EP2838882A1 - Formes solides de n-[2,4-bis(1,1-diméthyléthyle)-5-hydroxyphényle]-1,4-dihydro-4-oxoquinoline-3-carboxamide - Google Patents

Formes solides de n-[2,4-bis(1,1-diméthyléthyle)-5-hydroxyphényle]-1,4-dihydro-4-oxoquinoline-3-carboxamide

Info

Publication number
EP2838882A1
EP2838882A1 EP12720324.8A EP12720324A EP2838882A1 EP 2838882 A1 EP2838882 A1 EP 2838882A1 EP 12720324 A EP12720324 A EP 12720324A EP 2838882 A1 EP2838882 A1 EP 2838882A1
Authority
EP
European Patent Office
Prior art keywords
degrees
peak
crystalline solvate
compound
diffraction pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12720324.8A
Other languages
German (de)
English (en)
Inventor
Brian Luisi
Sneha Ghanshyam AREKAR
Adriana Costache
Kirk Raymond DINEHART
Steven C. Johnston
Bobbianna J. NEUBERT-LANGILLE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of EP2838882A1 publication Critical patent/EP2838882A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Definitions

  • the present invention relates to solid state forms, for example, crystalline solvate forms of N- [2,4-bis( 1 , 1 -dimethylethyl)-5 -hydroxyphenyl] - 1 ,4-dihydro-4-oxoquinoline-3 -carboxamide (Compound 1), which is a modulator of cystic fibrosis transmembrane conductance regulator ("CFTR").
  • CFTR cystic fibrosis transmembrane conductance regulator
  • the invention also relates to pharmaceutical compositions including crystalline forms ofN-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5- (trifluoromethyl)-l,4-dihydroquinoline-3 -carboxamide, and methods therewith.
  • Cystic fibrosis is a recessive genetic disease that affects approximately 30,000 children and adults in the United States and approximately 30,000 children and adults in Europe. Despite progress in the treatment of CF, there is no cure.
  • CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that encodes an epithelial chloride ion channel responsible for aiding in the regulation of salt and water absorption and secretion in various tissues.
  • CFTR cystic fibrosis transmembrane conductance regulator
  • Small molecule drugs known as potentiators that increase the probability of CFTR channel opening represent one potential therapeutic strategy to treat CF. Potentiators of this type are disclosed in WO
  • CFTR is a cAMP/ATP-mediated anion channel that is expressed in a variety of cells types, including absorptive and secretory epithelia cells, where it regulates anion flux across the membrane, as well as the activity of other ion channels and proteins.
  • epithelia cells normal functioning of CFTR is critical for the maintenance of electrolyte transport throughout the body, including respiratory and digestive tissue.
  • CFTR is composed of approximately 1480 amino acids that encode a protein made up of a tandem repeat of transmembrane domains, each containing six transmembrane helices and a nucleotide binding domain.
  • the two transmembrane domains are linked by a large, polar, regulatory (R)-domain with multiple phosphorylation sites that regulate channel activity and cellular trafficking.
  • R regulatory
  • the gene encoding CFTR has been identified and sequenced (See Gregory, R. J. et al. (1990) Nature 347:382-386; Rich, D. P. et al. (1990) Nature 347:358-362), (Riordan, J. R. et al.
  • CFTR cystic fibrosis
  • Cystic fibrosis affects approximately one in every 2,500 infants in the United States. Within the general United States population, up to 10 million people carry a single copy of the defective gene without apparent ill effects. In contrast, individuals with two copies of the CF associated gene suffer from the debilitating and fatal effects of CF, including chronic lung disease.
  • the most prevalent mutation is a deletion of phenylalanine at position 508 of the CFTR amino acid sequence, and is commonly referred to as AF508-CFTR. This mutation occurs in approximately 70% of the cases of cystic fibrosis and is associated with a severe disease.
  • CFTR transports a variety of molecules in addition to anions
  • this role represents one element in an important mechanism of transporting ions and water across the epithelium.
  • the other elements include the epithelial Na + channel, ENaC, Na + /2C17K + co-transporter, Na + -K + -ATPase pump and the basolateral membrane K + channels, that are responsible for the uptake of chloride into the cell.
  • N-[2,4-bis(l , 1 -dimethylethyl)-5-hydroxyphenyl]- 1 ,4-dihydro-4-oxoquinoline-3- carboxamide (Compound 1) is a potent and selective CFTR potentiator of wild-type and mutant (including e.g., AF508, Rl 17H, and G551D) forms of human CFTR.
  • N-[2,4-bis(l,l- dimethylethyl)-5-hydroxyphenyl]-l,4-dihydro-4-oxoquinoline-3-carboxamide is useful for treatment of adult patients with cystic fibrosis and at least one G551D-CFTR allele.
  • crystalline solvates forms of Compound 1 are designated as Forms D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, W, or Hydrate B, respectively.
  • the present invention is also directed to processes for making crystalline solvates of compound 1 designated as Forms D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, W, or Hydrate B, respectively.
  • the present invention is further directed to pharmaceutical compositions comprising a crystalline solvate of Compound 1 selected from Forms D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, W, or Hydrate B, respectively, and a pharmaceutically acceptable carrier or excipient.
  • the invention is further directed to therapeutic methods for treating CFTR-mediated diseases such as cystic fibrosis.
  • Figure 1 is an XRPD pattern of Form XX of Compound 1.
  • Figure 2 is an XRPD pattern of Form D of Compound 1.
  • Figure 3 is a thermogravimetric trace of Form D of Compound 1.
  • Figure 4 is an XRPD pattern of Form E of Compound 1.
  • Figure 5 is a thermogravimetric trace of Form E of Compound 1.
  • Figure 6 is an XRPD pattern of Form F of Compound 1.
  • Figure 7 is a thermogravimetric trace of Form F of Compound 1.
  • FIG. 8 is an XRPD pattern of Form G of Compound 1.
  • FIG. 10 is an XRPD pattern of Form H of Compound 1.
  • FIG. 11 is a thermogravimetric trace of Form H of Compound 1.
  • Figure 12 is an XRPD pattern of Form I of Compound 1.
  • FIG. 13 is a thermogravimetric trace of Form I of Compound 1.
  • Figure 14 is an XRPD pattern of Form J of Compound 1.
  • Figure 15 is a thermogravimetric trace of Form J of Compound 1.
  • Figure 16 is an XRPD pattern of Form K of Compound 1.
  • Figure 17 is a thermogravimetric trace of Form K of Compound 1.
  • Figure 18 is an XRPD pattern of Form L of Compound 1.
  • Figure 20 is an XRPD pattern of Form M of Compound 1.
  • Figure 21 is a thermogravimetric trace of Form M of Compound 1.
  • Figure 22 is an XRPD pattern of Form N of Compound 1.
  • FIG. 23 is a thermogravimetric trace of Form N of Compound 1.
  • Figure 24 is an XRPD pattern of Form O of Compound 1.
  • Figure 25 is a thermogravimetric trace of Form O of Compound 1.
  • Figure 26 is an XRPD pattern of Form P of Compound 1.
  • Figure 27 is a thermogravimetric trace of Form P of Compound 1.
  • Figure 28 is an XRPD pattern of Form Q of Compound 1.
  • Figure 30 is an XRPD pattern of Form R of Compound 1.
  • Figure 31 is a thermogravimetric trace of Form R of Compound 1.
  • Figure 32 is an XRPD pattern of Form S of Compound 1.
  • Figure 33 is a thermogravimetric trace of Form S of Compound 1.
  • Figure 34 is an XRPD pattern of Form T of Compound 1.
  • Figure 36 is an XRPD pattern of Hydrate B of Compound 1.
  • FIG. 37 is a thermogravimetric trace of Hydrate B of Compound 1.
  • Figure 38 is an XRPD pattern of Form W of Compound 1.
  • ABS-transporter as used herein means an ABC-transporter protein or a fragment thereof comprising at least one binding domain, wherein said protein or fragment thereof is present in vivo or in vitro.
  • binding domain as used herein means a domain on the ABC-transporter that can bind to a modulator. See, e.g., Hwang, T. C. et ah, J. Gen. Physiol. (1998): 777(3), 477-90.
  • CFTR cystic fibrosis transmembrane conductance regulator or a mutation thereof capable of regulator activity, including, but not limited to, AF508 CFTR, Rl 17H CFTR, and G551D CFTR (see, e.g., http://www.genet.sickkids.on.ca/cftr/, for CFTR mutations).
  • modulating means increasing or decreasing by a measurable amount.
  • treatment means the treatment or prevention of a CFTR related disorder as provided in the methods described herein, including curing, reducing the symptoms of or slowing the progress of said disorder.
  • the terms “treat” and “treating” are defined in accord the foregoing term “treatment”.
  • the term “normal CFTR” or “normal CFTR function” as used herein means wild-type like CFTR without any impairment due to environmental factors such as smoking, pollution, or anything that produces inflammation in the lungs.
  • reduced CFTR or “reduced CFTR function” as used herein means less than normal CFTR or less than normal CFTR function.
  • crystalline refers to compounds or compositions where the structural units are arranged in fixed geometric patterns or lattices, so that crystalline solids have rigid long range order.
  • the structural units that constitute the crystal structure can be atoms, molecules, or ions. Crystalline solids show definite melting points.
  • Solidvate as in the phrase “crystalline solvate” is a crystalline solid containing either stoichiometric or nonstoichiometric amounts of a solvent incorporated within the crystal structure.
  • a solvent incorporated within the crystal structure.
  • the solvates are also commonly known as hydrates.
  • the invention includes a crystalline solvate of Compound 1 , wherein the crystalline solvate is designated as a solid form selected from the group consisting of Form D, Form E, Form F, Form G, Form H, Form I, Form J, Form K, Form L, Form M, Form N, Form
  • the invention provides a crystalline solvate Form D of Compound
  • This crystalline solvate form is an acetonitrile solvate, or an acetonitrile/water 75/25 solvate.
  • crystalline solvate Form D is characterized by one or more peaks selected from the group consisting of 5.6 ⁇ 0.2 degrees, 6.0 ⁇ 0.2 degrees, 7.8 ⁇ 0.2 degrees, 13.5 ⁇ 0.2 degrees, 14.1 ⁇ 0.2 degrees, 14.7 ⁇ 0.2 degrees, and 16.2 ⁇ 0.2 degrees on a 2 ⁇ scale in an X-ray powder diffraction pattern.
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • crystalline solvate Form D is characterized by a peak at 5.6 ⁇ 0.2 degrees, a peak at 6.0 ⁇ 0.2 degrees, a peak at 7.8 ⁇ 0.2 degrees, a peak at 13.5 ⁇ 0.2 degrees, a peak at 14.1 ⁇ 0.2 degrees, a peak at 14.7 ⁇ 0.2 degrees, and a peak at 16.2 ⁇ 0.2 degrees on a 2 ⁇ scale in an X-ray powder diffraction pattern.
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • thermogravimetric trace of Form D is provided as Figure 3.
  • the invention provides a crystalline solvate Form E of Compound 1, which has an XRPD pattern as depicted in Figure 4.
  • This crystalline solvate form is a methylethyl ketone (MEK) solvate, a MEK/water 99/1 solvate, MEK/water 90/10 solvate, or a MEK water 80/20 solvate.
  • MEK methylethyl ketone
  • crystalline solvate Form E is characterized by one or more peaks selected from the group consisting of 8.0 ⁇ 0.2 degrees, 8.6 ⁇ 0.2 degrees, 10.1 ⁇ 0.2 degrees, 11.0 ⁇ 0.2 degrees, 11.9 ⁇ 0.2 degrees, 16.5 ⁇ 0.2 degrees, 17.1 ⁇ 0.2 degrees, and 18.1 ⁇ 0.2 degrees on a 2 ⁇ scale in an X-ray powder diffraction pattern.
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • crystalline solvate Form E is characterized by a peak at 8.0 ⁇ 0.2 degrees, a peak at 8.6 ⁇ 0.2 degrees, a peak at 10.1 ⁇ 0.2 degrees, a peak at
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • crystalline solvate Form E is characterized by one or more peaks selected from the group consisting of 6.8 ⁇ 0.2 degrees, 8.0 ⁇ 0.2 degrees, 8.6 ⁇ 0.2 degrees, 10.1 ⁇ 0.2 degrees, 10.7 ⁇ 0.2 degrees, 11.0 ⁇ 0.2 degrees, 11.9 ⁇ 0.2 degrees, 12.9 ⁇ 0.2 degrees, 14.0 ⁇ 0.2 degrees, 15.9 ⁇ 0.2 degrees, 16.5 ⁇ 0.2 degrees, 17.1 ⁇ 0.2 degrees, 18.1 ⁇ 0.2 degrees, 20.2 ⁇ 0.2 degrees, 21.1 ⁇ 0.2 degrees, 23.8 ⁇ 0.2 degrees, 24.3 ⁇ 0.2 degrees, 24.7 ⁇ 0.2 degrees, 25.5 ⁇ 0.2 degrees, and 26.6 ⁇ 0.2 degrees on a 2 ⁇ scale in an X- ray powder diffraction pattern.
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • crystalline solvate Form E is characterized by a peak at 6.8 ⁇ 0.2 degrees, a peak at 8.0 ⁇ 0.2 degrees, a peak at 8.6 ⁇ 0.2 degrees, a peak at
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • thermogravimetric trace of Form E is provided as Figure 5.
  • the invention provides a crystalline solvate Form F of Compound
  • Form F is characterized by one or more peaks selected from the group consisting of 7.2 ⁇ 0.2 degrees, 7.8 ⁇ 0.2 degrees, 9.4 ⁇ 0.2 degrees, 10.7 ⁇ 0.2 degrees, 12.1 ⁇ 0.2 degrees, 12.8 ⁇ 0.2 degrees, 14.1 ⁇ 0.2 degrees, and 14.7 ⁇ 0.2 degrees on a 2 ⁇ scale in an X-ray powder diffraction pattern.
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • Form F is characterized by a peak at 7.2 ⁇ 0.2 degrees, a peak at 7.8 ⁇ 0.2 degrees, a peak at 9.4 ⁇ 0.2 degrees, a peak at 10.7 ⁇ 0.2 degrees, a peak at 12.1 ⁇ 0.2 degrees, a peak at 12.8 ⁇ 0.2 degrees, a peak at 14.1 ⁇ 0.2 degrees, and a peak at 14.7 ⁇ 0.2 degrees on a 2 ⁇ scale in an X-ray powder diffraction pattern.
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • Form F is characterized by one or more peaks selected from the group consisting of 7.2 ⁇ 0.2 degrees, 7.8 ⁇ 0.2 degrees, 9.4 ⁇ 0.2 degrees, 10.7 ⁇ 0.2 degrees, 11.7 ⁇ 0.2 degrees, 12.1 ⁇ 0.2 degrees, 12.8 ⁇ 0.2 degrees, 13.2 ⁇ 0.2 degrees,
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • Form F is characterized by a peak at 7.2 ⁇ 0.2 degrees, a peak at 7.8 ⁇ 0.2 degrees, a peak at 9.4 ⁇ 0.2 degrees, a peak at 10.7 ⁇ 0.2 degrees, a peak at 11.7 ⁇ 0.2 degrees, a peak at 12.1 ⁇ 0.2 degrees, a peak at 12.8 ⁇ 0.2 degrees, a peak at
  • X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • thermogravimetric trace of Form F is provided as Figure 7.
  • the invention provides a crystalline solvate Form G of Compound 1, which has an XRPD pattern as depicted in Figure 8.
  • This crystalline solvate form is an isopropyl acetate solvate.
  • Form G is characterized by one or more peaks selected from the group consisting of 6.3 ⁇ 0.2 degrees, 7.3 ⁇ 0.2 degrees, and 12.4 ⁇ 0.2 degrees on a 2 ⁇ scale in an X-ray powder diffraction pattern.
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • Form G is characterized by a peak at 6.3 ⁇ 0.2 degrees, a peak at 7.3 ⁇ 0.2 degrees, and a peak at 12.4 ⁇ 0.2 degrees on a 2 ⁇ scale in an X-ray powder diffraction pattern.
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • thermogravimetric trace of Form G is provided as Figure 9.
  • the invention provides a crystalline solvate Form H of Compound
  • crystalline solvate Form H is characterized by one or more peaks selected from the group consisting of 7.9 ⁇ 0.2 degrees, 9.9 ⁇ 0.2 degrees, 10.4 ⁇ 0.2 degrees, 11.6 ⁇ 0.2 degrees, 12.1 ⁇ 0.2 degrees, 14.8 ⁇ 0.2 degrees, 16.0 ⁇ 0.2 degrees, and 17.9 ⁇ 0.2 degrees on a 2 ⁇ scale in an X-ray powder diffraction pattern.
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • crystalline solvate Form H is characterized by a peak at 7.9 ⁇ 0.2 degrees, a peak at 9.9 ⁇ 0.2 degrees, a peak at 10.4 ⁇ 0.2 degrees, a peak at
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • crystalline solvate Form H is characterized by one or more peaks selected from the group consisting of 5.9 ⁇ 0.2 degrees, 7.9 ⁇ 0.2 degrees, 9.9 ⁇ 0.2 degrees, 10.4 ⁇ 0.2 degrees, 10.9 ⁇ 0.2 degrees, 11.6 ⁇ 0.2 degrees, 12.1 ⁇ 0.2 degrees, 13.2 ⁇ 0.2 degrees, 13.8 ⁇ 0.2 degrees, 14.8 ⁇ 0.2 degrees, 16.0 ⁇ 0.2 degrees, 17.4 ⁇ 0.2 degrees, 17.9 ⁇ 0.2 degrees, 19.6 ⁇ 0.2 degrees, 20.6 ⁇ 0.2 degrees, 21.6 ⁇ 0.2 degrees, 22.5 ⁇ 0.2 degrees, 23.8 ⁇ 0.2 degrees, 24.8 ⁇ 0.2 degrees, and 26.9 ⁇ 0.2 degrees on a 20 scale in an X- ray powder diffraction pattern.
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • crystalline solvate Form H is characterized by a peak at 5.9 ⁇ 0.2 degrees, a peak at 7.9 ⁇ 0.2 degrees, a peak at 9.9 ⁇ 0.2 degrees, a peak at 10.4 ⁇ 0.2 degrees, a peak at 10.9 ⁇ 0.2 degrees, a peak at 11.6 ⁇ 0.2 degrees, a peak at 12.1 ⁇ 0.2 degrees, a peak at 13.2 ⁇ 0.2 degrees, a peak at 13.8 ⁇ 0.2 degrees, a peak at 14.8 ⁇ 0.2 degrees, a peak at 16.0 ⁇ 0.2 degrees, a peak at 17.4 ⁇ 0.2 degrees, a peak at 17.9 ⁇ 0.2 degrees, a peak at 19.6 ⁇ 0.2 degrees, a peak at 20.6 ⁇ 0.2 degrees, a peak at 21.6 ⁇ 0.2 degrees, a peak at 22.5 ⁇ 0.2 degrees, a peak at 23.8 ⁇ 0.2 degrees, a peak at 24.8 ⁇ 0.2 degrees, and a peak at 5.9 ⁇ 0.2 degrees, a
  • thermogravimetric trace of Form H is provided as Figure 11.
  • the invention provides a crystalline solvate Form I of Compound 1 , which has an XRPD pattern as depicted in Figure 12.
  • This crystalline solvate form is a MEK solvate.
  • crystalline solvate Form I is characterized by one or more peaks selected from the group consisting of 6.8 ⁇ 0.2 degrees, 8.4 ⁇ 0.2 degrees, 9.4 ⁇ 0.2 degrees, 10.2 ⁇ 0.2 degrees, 11.4 ⁇ 0.2 degrees, 17.1 ⁇ 0.2 degrees, 17.8 ⁇ 0.2 degrees, and 18.3 ⁇ 0.2 degrees on a 20 scale in an X-ray powder diffraction pattern.
  • peaks selected from the group consisting of 6.8 ⁇ 0.2 degrees, 8.4 ⁇ 0.2 degrees, 9.4 ⁇ 0.2 degrees, 10.2 ⁇ 0.2 degrees, 11.4 ⁇ 0.2 degrees, 17.1 ⁇ 0.2 degrees, 17.8 ⁇ 0.2 degrees, and 18.3 ⁇ 0.2 degrees on a 20 scale in an X-ray powder diffraction pattern.
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • crystalline solvate Form I is characterized by a peak at 6.8 ⁇ 0.2 degrees, a peak at 8.4 ⁇ 0.2 degrees, a peak at 9.4 ⁇ 0.2 degrees, a peak at 10.2 ⁇ 0.2 degrees, a peak at 11.4 ⁇ 0.2 degrees, a peak at 17.1 ⁇ 0.2 degrees, a peak at 17.8 ⁇ 0.2 degrees, and a peak at 18.3 ⁇ 0.2 degrees on a 20 scale in an X-ray powder diffraction pattern.
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • crystalline solvate Form I is characterized by one or more peaks selected from the group consisting of 5.8 ⁇ 0.2 degrees, 6.8 ⁇ 0.2 degrees, 7.2 ⁇ 0.2 degrees, 8.4 ⁇ 0.2 degrees, 8.8 ⁇ 0.2 degrees, 9.4 ⁇ 0.2 degrees, 10.2 ⁇ 0.2 degrees, 11.4 ⁇ 0.2 degrees, 12.7 ⁇ 0.2 degrees, 13.7 ⁇ 0.2 degrees, 14.8 ⁇ 0.2 degrees, 15.7 ⁇ 0.2 degrees, 17.1 ⁇ 0.2 degrees, 17.8 ⁇ 0.2 degrees, 18.3 ⁇ 0.2 degrees, 18.8 ⁇ 0.2 degrees, 20.2 ⁇ 0.2 degrees, 21.3 ⁇ 0.2 degrees, 23.9 ⁇ 0.2 degrees, and 25.2 ⁇ 0.2 degrees, on a 20 scale in an X-ray powder diffraction pattern.
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • crystalline solvate Form I is characterized by a peak at 5.8 ⁇ 0.2 degrees, a peak at 6.8 ⁇ 0.2 degrees, a peak at 7.2 ⁇ 0.2 degrees, a peak at 8.4 ⁇ 0.2 degrees, a peak at 8.8 ⁇ 0.2 degrees, a peak at 9.4 ⁇ 0.2 degrees, a peak at 10.2 ⁇ 0.2 degrees, a peak at 11.4 ⁇ 0.2 degrees, a peak at 12.7 ⁇ 0.2 degrees, a peak at 13.7 ⁇ 0.2 degrees, a peak at 14.8 ⁇ 0.2 degrees, a peak at 15.7 ⁇ 0.2 degrees, a peak at 17.1 ⁇ 0.2 degrees, a peak at 17.8 ⁇ 0.2 degrees, a peak at 18.3 ⁇ 0.2 degrees, a peak at 18.8 ⁇ 0.2 degrees, a peak at 20.2 ⁇ 0.2 degrees, a peak at 21.3 ⁇ 0.2 degrees, a peak at 23.9 ⁇ 0.2 degrees, and a
  • thermogravimetric trace of Form I is provided as Figure 13.
  • the invention provides a crystalline solvate Form J of Compound 1 , which has an XRPD pattern as depicted in Figure 14.
  • This crystalline solvate form is a
  • Form J is characterized by one or more peaks selected from the group consisting of 6.0 ⁇ 0.2 degrees, 7.9 ⁇ 0.2 degrees, 8.8 ⁇ 0.2 degrees, 9.9 ⁇ 0.2 degrees, 11.8 ⁇ 0.2 degrees, 17.7 ⁇ 0.2 degrees, 18.0 ⁇ 0.2 degrees, and 18.5 ⁇ 0.2 degrees on a 2 ⁇ scale in an X-ray powder diffraction pattern.
  • the X-ray powder diffraction pattern is obtained using Cu alpha radiation.
  • Form J is characterized by a peak at 6.0 ⁇ 0.2 degrees, a peak at 7.9 ⁇ 0.2 degrees, a peak at 8.8 ⁇ 0.2 degrees, a peak at 9.9 ⁇ 0.2 degrees, a peak at 11.8 ⁇ 0.2 degrees, a peak at 17.7 ⁇ 0.2 degrees, a peak at 18.0 ⁇ 0.2 degrees, and a peak at 18.5 ⁇ 0.2 degrees on a 2 ⁇ scale in an X-ray powder diffraction pattern.
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • Form J is characterized by one or more peaks selected from the group consisting of 6.0 ⁇ 0.2 degrees, 6.8 ⁇ 0.2 degrees, 7.9 ⁇ 0.2 degrees, 8.4 ⁇ 0.2 degrees, 8.8 ⁇ 0.2 degrees, 9.9 ⁇ 0.2 degrees, 11.8 ⁇ 0.2 degrees, 12.6 ⁇ 0.2 degrees, 13.6 ⁇ 0.2 degrees, 15.7 ⁇ 0.2 degrees, 16.7 ⁇ 0.2 degrees, 17.7 ⁇ 0.2 degrees, 18.0 ⁇ 0.2 degrees, 18.5 ⁇ 0.2 degrees, 19.3 ⁇ 0.2 degrees, 20.7 ⁇ 0.2 degrees, 22.6 ⁇ 0.2 degrees, 26.8 ⁇ 0.2 degrees, and 29.4 ⁇ 0.2 degrees on a 2 ⁇ scale in an X-ray powder diffraction pattern.
  • a further peaks selected from the group consisting of 6.0 ⁇ 0.2 degrees, 6.8 ⁇ 0.2 degrees, 7.9 ⁇ 0.2 degrees, 8.4 ⁇ 0.2 degrees, 8.8 ⁇ 0.2 degrees, 9.9 ⁇ 0.2 degrees, 1
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • Form J is characterized by a peak at 6.0 ⁇ 0.2 degrees, a peak at 6.8 ⁇ 0.2 degrees, a peak at 7.9 ⁇ 0.2 degrees, a peak at 8.4 ⁇ 0.2 degrees, a peak at 8.8 ⁇ 0.2 degrees, a peak at 9.9 ⁇ 0.2 degrees, a peak at 11.8 ⁇ 0.2 degrees, a peak at 12.6 ⁇ 0.2 degrees, a peak at 13.6 ⁇ 0.2 degrees, a peak at 15.7 ⁇ 0.2 degrees, a peak at 16.7 ⁇ 0.2 degrees, a peak at 17.7 ⁇ 0.2 degrees, a peak at 18.0 ⁇ 0.2 degrees, a peak at 18.5 ⁇ 0.2 degrees, a peak at 19.3 ⁇ 0.2 degrees, a peak at 20.7 ⁇ 0.2 degrees, a peak at 22.6 ⁇ 0.2 degrees, a peak at 26.8 ⁇ 0.2 degrees, and a peak at 29.4 ⁇ 0.2 degrees on a 2 ⁇ scale in an
  • thermogravimetric trace of Form J is provided as Figure 15.
  • the invention provides a crystalline solvate Form K of Compound
  • This crystalline solvate form is a methylethyl ketone (MEK) solvate, a MEK/water 99/1 solvate, MEK/water 90/10 solvate, or a MEK water 80/20 solvate.
  • MEK methylethyl ketone
  • crystalline solvate Form K is characterized by one or more peaks selected from the group consisting of 8.0 ⁇ 0.2 degrees, 8.5 ⁇ 0.2 degrees, 10.0 ⁇ 0.2 degrees, 11.8 ⁇ 0.2 degrees, 15.4 ⁇ 0.2 degrees, 15.9 ⁇ 0.2 degrees, 16.9 ⁇ 0.2 degrees, and 18.0 ⁇ 0.2 degrees on a 2 ⁇ scale in an X-ray powder diffraction pattern.
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • crystalline solvate Form K is characterized by a peak at 8.0 ⁇ 0.2 degrees, a peak at 8.5 ⁇ 0.2 degrees, a peak at 10.0 ⁇ 0.2 degrees, a peak at
  • the X-ray powder diffraction pattern is obtained using Cu alpha radiation.
  • crystalline solvate Form K is characterized by one or more peaks selected from the group consisting of 8.0 ⁇ 0.2 degrees, 8.5 ⁇ 0.2 degrees, 10.0 ⁇ 0.2 degrees, 11.8 ⁇ 0.2 degrees, 12.3 ⁇ 0.2 degrees, 14.2 ⁇ 0.2 degrees, 14.8 ⁇ 0.2 degrees, 15.4 ⁇ 0.2 degrees, 15.9 ⁇ 0.2 degrees, 16.9 ⁇ 0.2 degrees, 18.0 ⁇ 0.2 degrees, 18.5 ⁇ 0.2 degrees, 19.8 ⁇ 0.2 degrees, 20.2 ⁇ 0.2 degrees, 20.7 ⁇ 0.2 degrees, 21.0 ⁇ 0.2 degrees, 21.5 ⁇ 0.2 degrees, 22.7 ⁇ 0.2 degrees, and 29.5 ⁇ 0.2 degrees on a 2 ⁇ scale in an X-ray powder diffraction pattern.
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • crystalline solvate Form K is characterized by a peak at 8.0 ⁇ 0.2 degrees, a peak at 8.5 ⁇ 0.2 degrees, a peak at 10.0 ⁇ 0.2 degrees, a peak at 11.8 ⁇ 0.2 degrees, a peak at 12.3 ⁇ 0.2 degrees, a peak at 14.2 ⁇ 0.2 degrees, a peak at 14.8 ⁇ 0.2 degrees, a peak at 15.4 ⁇ 0.2 degrees, a peak at 15.9 ⁇ 0.2 degrees, a peak at 16.9 ⁇ 0.2 degrees, a peak at 18.0 ⁇ 0.2 degrees, a peak at 18.5 ⁇ 0.2 degrees, a peak at 19.8 ⁇ 0.2 degrees, a peak at 20.2 ⁇ 0.2 degrees, a peak at 20.7 ⁇ 0.2 degrees, a peak at 21.0 ⁇ 0.2 degrees, a peak at 21.5 ⁇ 0.2 degrees, a peak at 22.7 ⁇ 0.2 degrees, and a peak at 29.5 ⁇ 0.2 degrees on a
  • thermogravimetric trace of Form K is provided as Figure 17.
  • the invention provides a crystalline solvate Form L of Compound 1, which has an XRPD pattern as depicted in Figure 18.
  • This crystalline solvate form is an isopropyl acetate/water 95/5 solvate.
  • crystalline solvate Form L is characterized by one or more peaks selected from the group consisting of 7.9 ⁇ 0.2 degrees, 10.4 ⁇ 0.2 degrees, 10.9 ⁇ 0.2 degrees, 12.1 ⁇ 0.2 degrees, 14.8 ⁇ 0.2 degrees, 16.0 ⁇ 0.2 degrees, 18.6 ⁇ 0.2 degrees, and 20.5 ⁇ 0.2 degrees on a 2 ⁇ scale in an X-ray powder diffraction pattern.
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • crystalline solvate Form L is characterized by a peak at 7.9 ⁇ 0.2 degrees, a peak at 10.4 ⁇ 0.2 degrees, a peak at 10.9 ⁇ 0.2 degrees, a peak at 12.1 ⁇ 0.2 degrees, a peak at 14.8 ⁇ 0.2 degrees, a peak at 16.0 ⁇ 0.2 degrees, a peak at 18.6 ⁇ 0.2 degrees, and a peak at 20.5 ⁇ 0.2 degrees on a 2 ⁇ scale in an X-ray powder diffraction pattern.
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • crystalline solvate Form L is characterized by one or more peaks selected from the group consisting of 7.9 ⁇ 0.2 degrees, 10.0 ⁇ 0.2 degrees,
  • crystalline solvate Form L is characterized by a peak at 7.9 ⁇ 0.2 degrees, a peak at 10.0 ⁇ 0.2 degrees, a peak at 10.4 ⁇ 0.2 degrees, a peak at 10.9 ⁇ 0.2 degrees, a peak at 12.1 ⁇ 0.2 degrees, a peak at 13.2 ⁇ 0.2 degrees, a peak at 13.8 ⁇ 0.2 degrees, a peak at 14.8 ⁇ 0.2 degrees, a peak at 16.0 ⁇ 0.2 degrees, a peak at 16.9 ⁇ 0.2 degrees, a peak at 17.4 ⁇ 0.2 degrees, a peak at 18.6 ⁇ 0.2 degrees, a peak at 19.7 ⁇ 0.2 degrees, a peak at 20.5 ⁇ 0.2 degrees, a peak at 21.6 ⁇ 0.2 degrees, a peak at 22.1 ⁇ 0.2 degrees, a peak at a peak at a peak at 22.1 ⁇ 0.2 degrees, a peak at
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • thermogravimetric trace of Form L is provided as Figure 19.
  • the invention provides a crystalline solvate Form M of Compound 1 , which has an XRPD pattern as depicted in Figure 20.
  • This crystalline solvate form is a methylethyl ketone (MEK) solvate, or a MEK/water 99/1 solvate.
  • MEK methylethyl ketone
  • crystalline solvate Form M is characterized by one or more peaks selected from the group consisting of 5.2 ⁇ 0.2 degrees, 6.0 ⁇ 0.2 degrees, 6.9 ⁇ 0.2 degrees, 10.7 ⁇ 0.2 degrees, 12.3 ⁇ 0.2 degrees, 17.6 ⁇ 0.2 degrees, 18.3 ⁇ 0.2 degrees, and 21.1 ⁇ 0.2 degrees on a 20 scale in an X-ray powder diffraction pattern.
  • peaks selected from the group consisting of 5.2 ⁇ 0.2 degrees, 6.0 ⁇ 0.2 degrees, 6.9 ⁇ 0.2 degrees, 10.7 ⁇ 0.2 degrees, 12.3 ⁇ 0.2 degrees, 17.6 ⁇ 0.2 degrees, 18.3 ⁇ 0.2 degrees, and 21.1 ⁇ 0.2 degrees on a 20 scale in an X-ray powder diffraction pattern.
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • crystalline solvate Form M is characterized by a peak at 5.2 ⁇ 0.2 degrees, a peak at 6.0 ⁇ 0.2 degrees, a peak at 6.9 ⁇ 0.2 degrees, a peak at 10.7 ⁇ 0.2 degrees, a peak at 12.3 ⁇ 0.2 degrees, a peak at 17.6 ⁇ 0.2 degrees, a peak at 18.3 ⁇ 0.2 degrees, and a peak at 21.1 ⁇ 0.2 degrees on a 20 scale in an X-ray powder diffraction pattern.
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • crystalline solvate Form M is characterized by one or more peaks selected from the group consisting of 5.2 ⁇ 0.2 degrees, 6.0 ⁇ 0.2 degrees, 6.9 ⁇ 0.2 degrees, 8.0 ⁇ 0.2 degrees, 8.9 ⁇ 0.2 degrees, 10.7 ⁇ 0.2 degrees, 12.3 ⁇ 0.2 degrees, 13.0 ⁇ 0.2 degrees, 13.5 ⁇ 0.2 degrees, 14.4 ⁇ 0.2 degrees, 16.8 ⁇ 0.2 degrees, 17.3 ⁇ 0.2 degrees, 17.6 ⁇ 0.2 degrees, 18.3 ⁇ 0.2 degrees, 18.7 ⁇ 0.2 degrees, 19.8 ⁇ 0.2 degrees, 20.4 ⁇ 0.2 degrees, 21.1 ⁇ 0.2 degrees, 22.0 ⁇ 0.2 degrees, and 23.4 ⁇ 0.2 degrees, on a 20 scale in an X-ray powder diffraction pattern.
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • crystalline solvate Form M is characterized by a peak at 5.2 ⁇ 0.2 degrees, a peak at 6.0 ⁇ 0.2 degrees, a peak at 6.9 ⁇ 0.2 degrees, a peak at 8.0 ⁇ 0.2 degrees, a peak at 8.9 ⁇ 0.2 degrees, a peak at 10.7 ⁇ 0.2 degrees, a peak at 12.3 ⁇ 0.2 degrees, a peak at 13.0 ⁇ 0.2 degrees, a peak at 13.5 ⁇ 0.2 degrees, a peak at 14.4 ⁇ 0.2 degrees, a peak at 16.8 ⁇ 0.2 degrees, a peak at 17.3 ⁇ 0.2 degrees, a peak at 17.6 ⁇ 0.2 degrees, a peak at 18.3 ⁇ 0.2 degrees, a peak at 18.7 ⁇ 0.2 degrees, a peak at 19.8 ⁇ 0.2 degrees, a peak at 20.4 ⁇ 0.2 degrees, a peak at 21.1 ⁇ 0.2 degrees, a peak at 22.0 ⁇ 0.2 degrees, and a peak at 20.4 ⁇ 0.2 degrees, a
  • thermogravimetric trace of Form M is provided as Figure 21.
  • the invention provides a crystalline solvate Form N of Compound
  • crystalline solvate Form N is characterized by one or more peaks selected from the group consisting of 8.2 ⁇ 0.2 degrees, 9.7 ⁇ 0.2 degrees, 10.6 ⁇ 0.2 degrees, 11.5 ⁇ 0.2 degrees, 12.4 ⁇ 0.2 degrees, 16.6 ⁇ 0.2 degrees, 17.6 ⁇ 0.2 degrees, and 23.8 ⁇ 0.2 degrees on a 2 ⁇ scale in an X-ray powder diffraction pattern.
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • crystalline solvate Form N is characterized by a peak at 8.2 ⁇ 0.2 degrees, a peak at 9.7 ⁇ 0.2 degrees, a peak at 10.6 ⁇ 0.2 degrees, a peak at
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • crystalline solvate Form N is characterized by one or more peaks selected from the group consisting of 6.4 ⁇ 0.2 degrees, 7.6 ⁇ 0.2 degrees, 8.2 ⁇ 0.2 degrees, 9.1 ⁇ 0.2 degrees, 9.7 ⁇ 0.2 degrees, 10.2 ⁇ 0.2 degrees, 10.6 ⁇ 0.2 degrees, 11.5 ⁇ 0.2 degrees, 12.4 ⁇ 0.2 degrees, 14.1 ⁇ 0.2 degrees, 15.4 ⁇ 0.2 degrees, 16.6 ⁇ 0.2 degrees, 17.0 ⁇ 0.2 degrees, 17.6 ⁇ 0.2 degrees, 18.8 ⁇ 0.2 degrees, 21.4 ⁇ 0.2 degrees, 23.3 ⁇ 0.2 degrees, 23.8 ⁇ 0.2 degrees, 24.2 ⁇ 0.2 degrees, and 25.7 ⁇ 0.2 degrees on a 20 scale in an X-ray powder diffraction pattern.
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • crystalline solvate Form N is characterized by a peak at 6.4 ⁇ 0.2 degrees, a peak at 7.6 ⁇ 0.2 degrees, a peak at 8.2 ⁇ 0.2 degrees, a peak at 9.1 ⁇ 0.2 degrees, a peak at 9.7 ⁇ 0.2 degrees, a peak at 10.2 ⁇ 0.2 degrees, a peak at 10.6 ⁇ 0.2 degrees, a peak at 11.5 ⁇ 0.2 degrees, a peak at 12.4 ⁇ 0.2 degrees, a peak at 14.1 ⁇ 0.2 degrees, a peak at 15.4 ⁇ 0.2 degrees, a peak at 16.6 ⁇ 0.2 degrees, a peak at 17.0 ⁇ 0.2 degrees, a peak at 17.6 ⁇ 0.2 degrees, a peak at 18.8 ⁇ 0.2 degrees, a peak at 21.4 ⁇ 0.2 degrees, a peak at 23.3 ⁇ 0.2 degrees, a peak at 23.8 ⁇ 0.2 degrees, a peak at 24.2 ⁇ 0.2 degrees, and a peak at 21.4 ⁇ 0.2 degrees, a
  • thermogravimetric trace of Form N is provided as Figure 23.
  • the invention provides a crystalline solvate Form O of Compound
  • This crystalline solvate form is a methylethyl ketone (MEK) solvate, or a MEK/water 99/1 solvate.
  • MEK methylethyl ketone
  • crystalline solvate Form O is characterized by one or more peaks selected from the group consisting of 5.7 ⁇ 0.2 degrees, 8.5 ⁇ 0.2 degrees, 9.5 ⁇ 0.2 degrees, 11.4 ⁇ 0.2 degrees, 15.3 ⁇ 0.2 degrees, 17.2 ⁇ 0.2 degrees, 18.9 ⁇ 0.2 degrees, and
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • crystalline solvate Form O is characterized by a peak at 5.7 ⁇ 0.2 degrees, a peak at 8.5 ⁇ 0.2 degrees, a peak at 9.5 ⁇ 0.2 degrees, a peak at
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • crystalline solvate Form O is characterized by one or more peaks selected from the group consisting of 5.7 ⁇ 0.2 degrees, 7.5 ⁇ 0.2 degrees, 8.5 ⁇ 0.2 degrees, 9.5 ⁇ 0.2 degrees, 11.4 ⁇ 0.2 degrees, 13.2 ⁇ 0.2 degrees, 15.3 ⁇ 0.2 degrees, 16.3 ⁇ 0.2 degrees, 17.2 ⁇ 0.2 degrees, 17.5 ⁇ 0.2 degrees, 18.0 ⁇ 0.2 degrees, 18.9 ⁇ 0.2 degrees,
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • crystalline solvate Form O is characterized by a peak at 5.7 ⁇ 0.2 degrees, a peak at 7.5 ⁇ 0.2 degrees, a peak at 8.5 ⁇ 0.2 degrees, a peak at 9.5 ⁇ 0.2 degrees, a peak at 11.4 ⁇ 0.2 degrees, a peak at 13.2 ⁇ 0.2 degrees, a peak at 15.3 ⁇ 0.2 degrees, a peak at 16.3 ⁇ 0.2 degrees, a peak at 17.2 ⁇ 0.2 degrees, a peak at 17.5 ⁇ 0.2 degrees, a peak at 18.0 ⁇ 0.2 degrees, a peak at 18.9 ⁇ 0.2 degrees, a peak at 20.3 ⁇ 0.2 degrees, a peak at 20.6 ⁇ 0.2 degrees, a peak at 22.2 ⁇ 0.2 degrees, a peak at 23.1 ⁇ 0.2 degrees, a peak at 23.5 ⁇ 0.2 degrees, and a peak at 26.4 ⁇ 0.2 degrees on a 2 ⁇ scale in an X-ray powder d
  • the invention provides a crystalline solvate Form P of Compound 1, which has an XRPD pattern as depicted in Figure 26.
  • This crystalline solvate form is a MEK/water 90/10 solvate or a MEK/water 80/20 solvate.
  • crystalline solvate Form P is characterized by one or more peaks selected from the group consisting of 6.1 ⁇ 0.2 degrees, 7.4 ⁇ 0.2 degrees, 8.2 ⁇ 0.2 degrees, 9.1 ⁇ 0.2 degrees, 11.5 ⁇ 0.2 degrees, 12.3 ⁇ 0.2 degrees, 16.7 ⁇ 0.2 degrees, and 17.7 ⁇ 0.2 degrees on a 20 scale in an X-ray powder diffraction pattern.
  • peaks selected from the group consisting of 6.1 ⁇ 0.2 degrees, 7.4 ⁇ 0.2 degrees, 8.2 ⁇ 0.2 degrees, 9.1 ⁇ 0.2 degrees, 11.5 ⁇ 0.2 degrees, 12.3 ⁇ 0.2 degrees, 16.7 ⁇ 0.2 degrees, and 17.7 ⁇ 0.2 degrees on a 20 scale in an X-ray powder diffraction pattern.
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • crystalline solvate Form P is characterized by a peak at 6.1 ⁇ 0.2 degrees, a peak at 7.4 ⁇ 0.2 degrees, a peak at 8.2 ⁇ 0.2 degrees, a peak at 9.1 ⁇ 0.2 degrees, a peak at 1 1.5 ⁇ 0.2 degrees, a peak at 12.3 ⁇ 0.2 degrees, a peak at 16.7 ⁇ 0.2 degrees, and a peak at 17.7 ⁇ 0.2 degrees on a 2 ⁇ scale in an X-ray powder diffraction pattern.
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • crystalline solvate Form P is characterized by one or more peaks selected from the group consisting of 6.1 ⁇ 0.2 degrees, 7.4 ⁇ 0.2 degrees, 8.2 ⁇ 0.2 degrees, 9.1 ⁇ 0.2 degrees, 9.7 ⁇ 0.2 degrees, 10.6 ⁇ 0.2 degrees, 10.9 ⁇ 0.2 degrees, 11.5 ⁇ 0.2 degrees, 12.3 ⁇ 0.2 degrees, 16.1 ⁇ 0.2 degrees, 16.7 ⁇ 0.2 degrees, 17.0 ⁇ 0.2 degrees, 17.7 ⁇ 0.2 degrees, 18.9 ⁇ 0.2 degrees, 21.9 ⁇ 0.2 degrees, 23.3 ⁇ 0.2 degrees, 23.8 ⁇ 0.2 degrees, 24.9 ⁇ 0.2 degrees, and 25.8 ⁇ 0.2 degrees on a 20 scale in an X-ray powder diffraction pattern.
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • crystalline solvate Form P is characterized by a peak at 6.1 ⁇ 0.2 degrees, a peak at 7.4 ⁇ 0.2 degrees, a peak at 8.2 ⁇ 0.2 degrees, a peak at 9.1 ⁇ 0.2 degrees, a peak at 9.7 ⁇ 0.2 degrees, a peak at 10.6 ⁇ 0.2 degrees, a peak at 10.9 ⁇ 0.2 degrees, a peak at 11.5 ⁇ 0.2 degrees, a peak at 12.3 ⁇ 0.2 degrees, a peak at 16.1 ⁇ 0.2 degrees, a peak at 16.7 ⁇ 0.2 degrees, a peak at 17.0 ⁇ 0.2 degrees, a peak at 17.7 ⁇ 0.2 degrees, a peak at 18.9 ⁇ 0.2 degrees, a peak at 21.9 ⁇ 0.2 degrees, a peak at 23.3 ⁇ 0.2 degrees, a peak at 23.8 ⁇ 0.2 degrees, a peak at 24.9 ⁇ 0.2 degrees, and a peak at 25.8 ⁇ 0.2 degrees on
  • thermogravimetric trace of Form P is provided as Figure 27.
  • the invention provides a crystalline solvate Form Q of Compound 1, which has an XRPD pattern as depicted in Figure 28. This crystalline solvate form is a MEK/water 80/20 solvate.
  • Form Q is characterized by one or more peaks selected from the group consisting of 6.3 ⁇ 0.2 degrees, 7.6 ⁇ 0.2 degrees, 8.4 ⁇ 0.2 degrees, 11.1 ⁇ 0.2 degrees, 12.5 ⁇ 0.2 degrees, 16.4 ⁇ 0.2 degrees, 16.9 ⁇ 0.2 degrees, and 18.0 ⁇ 0.2 degrees on a 2 ⁇ scale in an X-ray powder diffraction pattern.
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • Form Q is characterized by a peak at 6.3 ⁇ 0.2 degrees, a peak at 7.6 ⁇ 0.2 degrees, a peak at 8.4 ⁇ 0.2 degrees, a peak at 11.1 ⁇ 0.2 degrees, a peak at 12.5 ⁇ 0.2 degrees, a peak at 16.4 ⁇ 0.2 degrees, a peak at 16.9 ⁇ 0.2 degrees, and a peak at 18.0 ⁇ 0.2 degrees on a 2 ⁇ scale in an X-ray powder diffraction pattern.
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • Form Q is characterized by one or more peaks selected from the group consisting of 6.3 ⁇ 0.2 degrees, 7.6 ⁇ 0.2 degrees, 8.4 ⁇ 0.2 degrees, 11.1 ⁇ 0.2 degrees, 11.7 ⁇ 0.2 degrees, 12.5 ⁇ 0.2 degrees, 14.7 ⁇ 0.2 degrees, 16.4 ⁇ 0.2 degrees, 16.9 ⁇ 0.2 degrees, 17.3 ⁇ 0.2 degrees, 18.0 ⁇ 0.2 degrees, 18.8 ⁇ 0.2 degrees, 20.6 ⁇ 0.2 degrees, 21.0 ⁇ 0.2 degrees, 22.2 ⁇ 0.2 degrees, 24.1 ⁇ 0.2 degrees, 25.1 ⁇ 0.2 degrees, and 27.4 ⁇ 0.2 degrees on a 2 ⁇ scale in an X-ray powder diffraction pattern.
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • Form Q is characterized by a peak at 6.3 ⁇ 0.2 degrees, a peak at 7.6 ⁇ 0.2 degrees, a peak at 8.4 ⁇ 0.2 degrees, a peak at 11.1 ⁇ 0.2 degrees, a peak at 11.7 ⁇ 0.2 degrees, a peak at 12.5 ⁇ 0.2 degrees, a peak at 14.7 ⁇ 0.2 degrees, a peak at 16.4 ⁇ 0.2 degrees, a peak at 16.9 ⁇ 0.2 degrees, a peak at 17.3 ⁇ 0.2 degrees, a peak at 18.0 ⁇
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • thermogravimetric trace of Form Q is provided as Figure 29.
  • the invention provides a crystalline solvate Form R of Compound
  • crystalline solvate Form R is characterized by one or more peaks selected from the group consisting of 6.7 ⁇ 0.2 degrees, 7.7 ⁇ 0.2 degrees, 13.2 ⁇ 0.2 degrees, 15.1 ⁇ 0.2 degrees, and 17.8 ⁇ 0.2 degrees on a 20 scale in an X-ray powder diffraction pattern.
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • crystalline solvate Form R is characterized by a peak at 6.7 ⁇ 0.2 degrees, a peak at 7.7 ⁇ 0.2 degrees, a peak at 13.2 ⁇ 0.2 degrees, a peak at 15.1 ⁇ 0.2 degrees, and a peak at 17.8 ⁇ 0.2 degrees on a 2 ⁇ scale in an X-ray powder diffraction pattern.
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • thermogravimetric trace of Form R is provided as Figure 31.
  • the invention provides a crystalline solvate Form S of Compound 1, which has an XRPD pattern as depicted in Figure 32.
  • This crystalline solvate form is a MEK/water 80/20 solvate.
  • crystalline solvate Form S is characterized by one or more peaks selected from the group consisting of 4.8 ⁇ 0.2 degrees, 7.7 ⁇ 0.2 degrees, 8.2 ⁇ 0.2 degrees, 9.6 ⁇ 0.2 degrees, 11.6 ⁇ 0.2 degrees, 15.1 ⁇ 0.2 degrees, 18.3 ⁇ 0.2 degrees, and
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • crystalline solvate Form S is characterized by a peak at 4.8 ⁇ 0.2 degrees, a peak at 7.7 ⁇ 0.2 degrees, a peak at 8.2 ⁇ 0.2 degrees, a peak at 9.6 ⁇ 0.2 degrees, a peak at 11.6 ⁇ 0.2 degrees, a peak at 15.1 ⁇ 0.2 degrees, a peak at 18.3 ⁇ 0.2 degrees, and a peak at 23.6 ⁇ 0.2 degrees on a 20 scale in an X-ray powder diffraction pattern.
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • crystalline solvate Form S is characterized by one or more peaks selected from the group consisting of 4.8 ⁇ 0.2 degrees, 5.7 ⁇ 0.2 degrees, 7.7 ⁇ 0.2 degrees, 8.2 ⁇ 0.2 degrees, 8.6 ⁇ 0.2 degrees, 9.6 ⁇ 0.2 degrees, 11.3 ⁇ 0.2 degrees, 11.6 ⁇ 0.2 degrees, 12.3 ⁇ 0.2 degrees, 13.9 ⁇ 0.2 degrees, 15.1 ⁇ 0.2 degrees, 15.5 ⁇ 0.2 degrees, 15.9 ⁇ 0.2 degrees, 16.5 ⁇ 0.2 degrees, 17.6 ⁇ 0.2 degrees, 18.3 ⁇ 0.2 degrees, 19.4 ⁇ 0.2 degrees,
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • crystalline solvate Form S is characterized by a peak at 4.8 ⁇ 0.2 degrees, a peak at 5.7 ⁇ 0.2 degrees, a peak at 7.7 ⁇ 0.2 degrees, a peak at 8.2 ⁇ 0.2 degrees, a peak at 8.6 ⁇ 0.2 degrees, a peak at 9.6 ⁇ 0.2 degrees, a peak at 11.3 ⁇ 0.2 degrees, a peak at 11.6 ⁇ 0.2 degrees, a peak at 12.3 ⁇ 0.2 degrees, a peak at 13.9 ⁇ 0.2 degrees, a peak at 15.1 ⁇ 0.2 degrees, a peak at 15.5 ⁇ 0.2 degrees, a peak at 15.9 ⁇ 0.2 degrees, a peak at
  • the X-ray powder diffraction pattern is obtained using Cu alpha radiation.
  • thermogravimetric trace of Form S is provided as Figure 33.
  • the invention provides a crystalline solvate Form T of Compound
  • crystalline solvate Form T is characterized by one or more peaks selected from the group consisting of 4.9 ⁇ 0.2 degrees, 8.3 ⁇ 0.2 degrees, 9.8 ⁇ 0.2 degrees, 11.6 ⁇ 0.2 degrees, 18.1 ⁇ 0.2 degrees, 18.7 ⁇ 0.2 degrees, 21.1 ⁇ 0.2 degrees, and 24.0 ⁇ 0.2 degrees on a 20 scale in an X-ray powder diffraction pattern.
  • peaks selected from the group consisting of 4.9 ⁇ 0.2 degrees, 8.3 ⁇ 0.2 degrees, 9.8 ⁇ 0.2 degrees, 11.6 ⁇ 0.2 degrees, 18.1 ⁇ 0.2 degrees, 18.7 ⁇ 0.2 degrees, 21.1 ⁇ 0.2 degrees, and 24.0 ⁇ 0.2 degrees on a 20 scale in an X-ray powder diffraction pattern.
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • crystalline solvate Form T is characterized by a peak at 4.9 ⁇ 0.2 degrees, a peak at 8.3 ⁇ 0.2 degrees, a peak at 9.8 ⁇ 0.2 degrees, a peak at
  • crystalline solvate Form T is characterized by one or more peaks selected from the group consisting of 4.9 ⁇ 0.2 degrees, 7.8 ⁇ 0.2 degrees, 8.3 ⁇ 0.2 degrees, 8.5 ⁇ 0.2 degrees, 9.8 ⁇ 0.2 degrees, 11.6 ⁇ 0.2 degrees, 14.2 ⁇ 0.2 degrees, 15.2 ⁇ 0.2 degrees, 15.7 ⁇ 0.2 degrees, 17.3 ⁇ 0.2 degrees, 18.1 ⁇ 0.2 degrees, 18.7 ⁇ 0.2 degrees, 19.9 ⁇ 0.2 degrees, 21.1 ⁇ 0.2 degrees, 21.3 ⁇ 0.2 degrees, 23.0 ⁇ 0.2 degrees, 23.7 ⁇ 0.2 degrees, 24.0 ⁇ 0.2 degrees, 25.0 ⁇ 0.2 degrees, and 25.6 ⁇ 0.2 degrees on a 20 scale in an X-ray powder diffraction pattern.
  • crystalline solvate Form T is characterized by a peak at 4.9 ⁇ 0.2 degrees, a peak at 7.8 ⁇ 0.2 degrees, a peak at 8.3 ⁇ 0.2 degrees, a peak at 8.5 ⁇ 0.2 degrees, a peak at 9.8 ⁇ 0.2 degrees, a peak at 11.6 ⁇ 0.2 degrees, a peak at 14.2 ⁇ 0.2 degrees, a peak at 15.2 ⁇ 0.2 degrees, a peak at 15.7 ⁇ 0.2 degrees, a peak at 17.3 ⁇ 0.2 degrees, a peak at 18.1 ⁇ 0.2 degrees, a peak at 18.7 ⁇ 0.2 degrees, a peak at 19.9 ⁇ 0.2 degrees, a peak at 21.1 ⁇ 0.2 degrees, a peak at 21.3 ⁇ 0.2 degrees, a peak at 23.0 ⁇ 0.2 degrees, a peak at 23.7 ⁇ 0.2 degrees,
  • thermogravimetric trace of Form T is provided as Figure 35.
  • Form T A single crystal was obtained for Form T, which has the following unit cell dimensions:
  • the invention provides a crystalline solvate of Compound 1 designated as Hydrate B, which has an XRPD pattern as depicted in Figure 36.
  • Hydrate B is characterized by one or more peaks selected from the group consisting of 4.9 ⁇ 0.2 degrees, 6.0 ⁇ 0.2 degrees, 7.2 ⁇ 0.2 degrees, 8.9 ⁇ 0.2 degrees, 10.1 ⁇ 0.2 degrees, 10.7 ⁇ 0.2 degrees, 11.3 ⁇ 0.2 degrees, and 11.9 ⁇
  • X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • Hydrate B is characterized by a peak at 4.9 ⁇
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • thermogravimetric trace of Hydrate B is provided as Figure 37.
  • the invention provides a crystalline solvate of Compound 1 designated as Form W, which has an XRPD pattern as depicted in Figure 38.
  • Form W is characterized by one or more peaks selected from the group consisting of 5.5 ⁇ 0.2 degrees, 10.9 ⁇ 0.2 degrees, 12.1 ⁇ 0.2 degrees, 13.3 ⁇ 0.2 degrees, 14.6 ⁇ 0.2 degrees, 17.2 ⁇ 0.2 degrees, 18.8 ⁇ 0.2 degrees, and 21.8 ⁇ 0.2 degrees on a 2 ⁇ scale in an X-ray powder diffraction pattern.
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • Form W is characterized by a peak at 5.5 ⁇ 0.2 degrees, a peak at 10.9 ⁇ 0.2 degrees, a peak at 12.1 ⁇ 0.2 degrees, a peak at 13.3 ⁇ 0.2 degrees, a peak at 14.6 ⁇ 0.2 degrees, a peak at 17.2 ⁇ 0.2 degrees, a peak at 18.8 ⁇ 0.2 degrees, and a peak at 21.8 ⁇ 0.2 degrees on a 2 ⁇ scale in an X-ray powder diffraction pattern.
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • Form W is characterized by one or more peaks selected from the group consisting of 5.5 ⁇ 0.2 degrees, 5.9 ⁇ 0.2 degrees, 7.6 ⁇ 0.2 degrees, 10.9 ⁇ 0.2 degrees, 12.1 ⁇ 0.2 degrees, 13.3 ⁇ 0.2 degrees, 14.6 ⁇ 0.2 degrees, 17.2 ⁇ 0.2 degrees, 18.8 ⁇ 0.2 degrees, 21.8 ⁇ 0.2 degrees, 22.5 ⁇ 0.2 degrees, 23.2 ⁇ 0.2 degrees, 23.7 ⁇ 0.2 degrees, 25.0 ⁇ 0.2 degrees, and 25.6 ⁇ 0.2 degrees on a 2 ⁇ scale in an X-ray powder diffraction pattern.
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • Form W is characterized by a peak at 5.5 ⁇ 0.2 degrees, a peak at 5.9 ⁇ 0.2 degrees, a peak at 7.6 ⁇ 0.2 degrees, a peak at 10.9 ⁇ 0.2 degrees, a peak at 12.1 ⁇ 0.2 degrees, a peak at 13.3 ⁇ 0.2 degrees, a peak at 14.6 ⁇ 0.2 degrees, a peak at 17.2 ⁇ 0.2 degrees, a peak at 18.8 ⁇ 0.2 degrees, a peak at 21.8 ⁇ 0.2 degrees, a peak at 22.5 ⁇ 0.2 degrees, a peak at 23.2 ⁇ 0.2 degrees, a peak at 23.7 ⁇ 0.2 degrees, a peak at 25.0 ⁇ 0.2 degrees, and a peak at 25.6 ⁇ 0.2 degrees on a 2 ⁇ scale in an X-ray powder diffraction pattern.
  • the X-ray powder diffraction pattern is obtained using Cu K alpha radiation.
  • thermogravimetric trace of Form W is provided as Figure 39.
  • the invention provides a process for making a crystalline solvate Form D of Compound 1 comprising:
  • At least one of the solvents is acetonitrile.
  • the solvent is acetonitrile/water 75/25.
  • the invention provides a process for making a crystalline solvate Form E of Compound 1 comprising:
  • At least one of the solvents is MEK.
  • the solvent is MEK/water.
  • the solvent is MEK/water 99/1.
  • the solvent is MEK/water 90/10.
  • the solvent is MEK/water 80/20.
  • the invention provides a process for making a crystalline solvate Form E of Compound 1 comprising:
  • the solvent is MEK/water 90/10.
  • the solvent is MEK/water 80/20.
  • the invention provides a process for making a crystalline solvate Form E of Compound 1 comprising:
  • the solvent is MEK/water 90/10.
  • the solvent is MEK/water 80/20.
  • the invention provides a process for making a crystalline solvate Form F of Compound 1 comprising:
  • the solvent is acetonitrile water 75/25.
  • the invention provides a process for making a semi-crystalline solvate Form G of Compound 1 comprising:
  • the solvent is isopropyl acetate.
  • the invention provides a process for making a crystalline solvate
  • Form H of Compound 1 comprising:
  • the solvent is isopropyl acetate/water 95/5.
  • the invention provides a process for making a crystalline solvate Form I of
  • Compound 1 comprising:
  • the invention provides a process for making a crystalline solvate Form J of Compound 1 comprising:
  • the solvent is MEK/water 99/1.
  • the invention provides a process for making a crystalline solvate Form K of Compound 1 comprising:
  • At least one of the solvents is MEK.
  • the solvent is MEK/water.
  • the solvent is MEK/water 99/1.
  • the solvent is MEK/water 90/10.
  • the solvent is MEK/water 80/20.
  • the antisolvent is a non-polar hydrocarbon solvent such as pentane hexane, heptane, octane, nonane, or the like. More particularly, the antisolvent is n-hexane.
  • the invention provides a process for making a crystalline solvate Form L of Compound 1 comprising:
  • the solvent is isopropyl acetate/water 95/5.
  • the process occurs from 12 hours to 3 weeks.
  • the process occurs from 24 hours to 2 weeks.
  • the invention provides a process for making a crystalline solvate Form M of Compound 1 comprising:
  • the mixture further comprises one or more polymeric additives.
  • the additives are selected from hydroxypropyl methyl cellulose (HPMC) and sodium lauryl sulfate (SLS).
  • the invention provides a process for making a crystalline solvate Form N of Compound 1 comprising:
  • the mixture further comprises one or more polymeric additives.
  • the additives are selected from HPMC and SLS.
  • the invention provides a process for making a crystalline solvate Form O of Compound 1 comprising:
  • the mixture further comprises one or more polymeric additives.
  • the additives are HPMC and SLS.
  • the solvent is MEK.
  • the slurry is heated at 70 °C for from 12 hours to 3 weeks, more preferably from 24 hours to 2 weeks.
  • the solvent is MEK/H 2 0 99/1.
  • the slurry is heated at 70 °C for from 6 hours to 1 week, more preferably from 12 hours to 24 hours.
  • the invention provides a process for making a crystalline solvate Form P of Compound 1 comprising:
  • the mixture further comprises one or more polymeric additives.
  • the additives are HPMC and SLS.
  • the invention provides a process for making a crystalline solvate Form Q of Compound 1 comprising:
  • the mixture further comprises one or more polymeric additives.
  • the additives are HPMC and SLS.
  • the invention provides a process for making a crystalline solvate Form R of Compound 1 comprising:
  • the invention provides a process for making a crystalline solvate Form S of Compound 1 comprising:
  • the invention provides a process for making a crystalline solvate Form T of Compound 1 comprising:
  • the invention provides a process for making a crystalline solvate Hydrate B of Compound 1.
  • the process for making a crystalline solvate Hydrate B comprises:
  • the process for making a crystalline solvate Hydrate B comprises:
  • the ratio of amorphous Compound 1 and water is about 1:1.
  • the invention provides a crystalline solvate of Compound 1, wherein the solvent is a polar solvent, more preferably a polar aprotic solvent.
  • the polar aprotic solvent is acetonitrile, MEK, or isopropyl acetate.
  • the invention provides a crystalline solvate of Compound 1, wherein the solvent is a polar solvent, more preferably a polar aprotic solvent, optionally additionally comprising water.
  • the invention provides a crystalline solvate of Compound 1, wherein the solvent is selected from the group consisting of acetonitrile, acetonitrile/water, isopropyl acetate, isopropyl acetate/water, methylethyl ketone, and methylethyl ketone/water.
  • the solvent is selected from the group consisting of acetonitrile, acetonitrile/water, isopropyl acetate, isopropyl acetate/water, methylethyl ketone, and methylethyl ketone/water.
  • the solvent is acetonitrile.
  • the solvent is acetonitrile/water 75/25.
  • the solvent is isopropyl acetate.
  • the solvent is isopropyl acetate/water 95/5.
  • the solvent is MEK.
  • the solvent is MEK/water 99/1.
  • the solvent is MEK/water 90/10.
  • the solvent is MEK/water 80/20.
  • the solvent is acetonitrile or acetonitrile/water and the crystalline solvate is Form D, Form F, or Form R, as described above.
  • the solvent is isopropyl acetate or isopropyl acetate/water and the crystalline solvate, which is Form G, Form H, Form L, or Form T.
  • the solvent is methylethyl ketone or methylethyl ketone/water and the crystalline solvate is Form E, Form I, Form J, Form K, Form M, Form N, Form O, Form P, or Form S.
  • the invention provides a process for making a crystalline solvate of Compound 1 comprising:
  • the solvent is acetonitrile or acetonitrile/water and the crystalline solvate is Form D.
  • the solvent is methylethyl ketone or methylethyl ketone/water and the crystalline solvate is Form E.
  • the invention provides a process for making a crystalline solvate of Compound 1 comprising:
  • the solvent is acetonitrile/water and the crystalline solvate is Form F.
  • the solvent is isopropyl acetate and the crystalline solvate is Form G.
  • the solvent isopropyl acetate/water and the crystalline solvate is Form H.
  • the solvent methylethyl ketone and the crystalline solvate is Form I.
  • the solvent is methylethyl ketone/water and the crystalline solvate is Form J or Form E.
  • the invention provides a process for making a crystalline solvate of Compound 1 comprising: a) slurrying amorphous of Compound 1 in at least one solvent;
  • the solvent is methylethyl ketone containing 0 to 30 percent water and the crystalline solvate is Form K.
  • the solvent is isopropyl acetate/water and the crystalline solvate is Form T.
  • the invention provides a process for making a crystalline solvate of Compound 1 comprising:
  • the solvent is isopropyl acetate containing water and the crystalline solvate is Form L.
  • the invention provides a process for making a crystalline solvate of Compound 1 comprising:
  • the crystalline solvate is Form M or Form N.
  • the invention provides a process for making a crystalline solvate of Compound 1 comprising:
  • the crystalline solvate is solvate is Form O, Form P, or Form Q.
  • the invention provides a process for making a crystalline solvate of Compound 1 comprising:
  • the solvate form used in step (a) is Form D and the solvate form isolated is Form R.
  • the solvate form used in step (a) is Form K and the solvate form isolated is Form S.
  • the invention provides crystalline solvate Form D of Compound 1 prepared by the process comprising
  • At least one of the solvents is acetonitrile.
  • the solvent is acetonitrile/water 75/25.
  • the invention provides crystalline solvate Form E of Compound 1 prepared by the process comprising:
  • At least one of the solvents is MEK.
  • the solvent is MEK/water.
  • the solvent is MEK/water 99/1.
  • the solvent is MEK/water 90/10.
  • the solvent is MEK/water 80/20.
  • the invention provides crystalline solvate Form E of Compound 1 prepared by the process comprising:
  • the solvent is MEK/water 90/10.
  • the solvent is MEK/water 80/20.
  • the invention provides crystalline solvate Form E of Compound 1 prepared by the process comprising:
  • the solvent is MEK water 90/10.
  • the solvent is MEK/water 80/20.
  • the invention provides crystalline solvate Form F of Compound 1 prepared by the process comprising:
  • the solvent is acetonitrile water 75/25.
  • the invention provides crystalline solvate Form G of Compound 1 prepared by the process comprising:
  • the solvent is isopropyl acetate.
  • the invention provides crystalline solvate Form H of Compound 1 prepared by the process comprising:
  • the solvent is isopropyl acetate/water 95/5.
  • the invention provides crystalline solvate Form I of Compound 1 prepared by the process comprising:
  • the invention provides crystalline solvate Form J of Compound 1 prepared by the process comprising:
  • the solvent is MEK/water 99/1.
  • the invention provides crystalline solvate Form K of Compound 1 prepared by the process comprising:
  • At least one of the solvents is MEK.
  • the solvent is MEK/water.
  • the solvent is MEK water 99/1.
  • the solvent is MEK/water 90/10.
  • the solvent is MEK water 80/20.
  • the antisolvent is a non-polar hydrocarbon solvent such as pentane hexane, heptane, octane, nonane, or the like. More particularly, the antisolvent is n-hexane.
  • the invention provides crystalline solvate Form L of Compound 1 prepared by the process: comprising:
  • the solvent is isopropyl acetate/water 95/5.
  • the process occurs from 12 hours to 3 weeks.
  • the process occurs from 24 hours to 2 weeks.
  • the invention provides crystalline solvate Form M of Compound 1 prepared by the process comprising:
  • the mixture further comprises one or more polymeric additives.
  • the additives are selected from hydroxypropyl methyl cellulose (HPMC) and sodium lauryl sulfate (SLS).
  • the invention provides crystalline solvate Form N of Compound 1 prepared by the process comprising:
  • the mixture further comprises one or more polymeric additives.
  • the additives are selected from HPMC and SLS.
  • the invention provides crystalline solvate Form O of Compound 1 prepared by the process comprising: a) at 70 °C, slurrying amorphous Compound 1 in methylethyl ketone containing 0 percent to 1 percent water for 6 hours to 4 weeks to form a mixture;
  • the mixture further comprises one or more polymeric additives.
  • the additives are HPMC and SLS.
  • the solvent is MEK.
  • the slurry is heated at 70 °C for from 12 hours to 3 weeks, more preferably from 24 hours to 2 weeks.
  • the solvent is MEK/H 2 0 99/1.
  • the slurry is heated at 70 °C for from 6 hours to 1 week, more preferably from 12 hours to 24 hours.
  • the invention provides crystalline solvate Form P of Compound 1 prepared by the process comprising:
  • the mixture further comprises one or more polymeric additives.
  • the additives are HPMC and SLS.
  • the invention provides crystalline solvate Form Q of Compound 1 prepared by the process comprising:
  • the mixture further comprises one or more polymeric additives.
  • the additives are HPMC and SLS.
  • the invention provides crystalline solvate Form R of Compound 1 prepared by the process comprising:
  • the invention provides crystalline solvate Form S of Compound 1 prepared by the process comprising:
  • the invention provides crystalline solvate Form T of Compound 1 prepared by the process comprising:
  • compositions comprising Forms D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, W, or Hydrate B as described herein, and optionally comprise a pharmaceutically acceptable carrier, adjuvant or vehicle.
  • these compositions optionally further comprise one or more additional therapeutic agents.
  • compositions of the present invention additionally comprise a pharmaceutically acceptable carrier, adjuvant, or vehicle, which, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
  • a pharmaceutically acceptable carrier, adjuvant, or vehicle which, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
  • composition its use is contemplated to be within the scope of this invention.
  • materials which can serve as pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, or potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, wool fat, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powder
  • buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen- free water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator.
  • buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen- free water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, pre
  • the invention provides a method of treating or lessening the severity of a disease in a patient comprising administering to said patient form D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, W, or Hydrate B, or any combination of these forms, as described herein, and said disease is selected from cystic fibrosis, asthma, smoke induced COPD, chronic bronchitis, rhinosinusitis, constipation, pancreatitis, pancreatic insufficiency, male infertility caused by congenital bilateral absence of the vas deferens (CBAVD), mild pulmonary disease, idiopathic pancreatitis, allergic bronchopulmonary aspergillosis (ABPA), liver disease, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis deficiencies, such as protein C deficiency, Type 1 hereditary angioe
  • hypofibrinogenemia ACT deficiency
  • Diabetes insipidus DI
  • neurohypophyseal DI nephrogenic DI
  • Charcot-Marie Tooth syndrome Pelizaeus-Merzbacher disease
  • neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, progressive supranuclear palsy, Pick's disease, several polyglutamine neurological disorders such as Huntington's, spinocerebellar ataxia type I, spinal and bulbar muscular atrophy, dentatorubral pallidoluysian atrophy, and myotonic dystrophy, as well as spongiform encephalopathies, such as hereditary Creutzfeldt- Jakob disease (due to prion protein processing defect), Fabry disease, Straussler-Scheinker syndrome, COPD, dry-eye disease, or Sjogren's disease, Osteoporosis, Osteopenia, bone healing and bone growth (including bone repair, bone regeneration, reducing bone resorption and increasing bone deposition), Gorham's Syndrome, chloride channelopathies such as myotonia congenita (Thomson and Becker forms), Bartter's syndrome type III, Dent's
  • the method includes treating or lessening the severity of cystic fibrosis in a patient comprising administering to said patient form D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, W, or Hydrate B, or any combination of these forms, as described herein.
  • the patient possesses mutant forms of human CFTR.
  • the patient possesses one or more of the following mutations AF508, Rl 17H, and G551D of human CFTR.
  • the method includes treating or lessening the severity of cystic fibrosis in a patient possessing the AF508 mutation of human CFTR
  • the method includes treating or lessening the severity of cystic fibrosis in a patient possessing the G551D mutation of human CFTR comprising administering to said patient form D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, W, or Hydrate B, or any combination of these forms, as described herein.
  • the method includes treating or lessening the severity of cystic fibrosis in a patient possessing the G551D mutation of human CFTR comprising administering to said patient form D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, W, or Hydrate B, or any combination of these forms, as described herein.
  • the method includes treating or lessening the severity of cystic fibrosis in a patient possessing the AF508 mutation of human CFTR on at least one allele comprising administering to said patient form D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, W, or Hydrate B, or any combination of these forms, as described herein.
  • the method includes treating or lessening the severity of cystic fibrosis in a patient possessing the AF508 mutation of human CFTR on both alleles comprising administering to said patient form D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, W, or Hydrate B, or any combination of these forms, as described herein.
  • the method includes treating or lessening the severity of cystic fibrosis in a patient possessing the G55 ID mutation of human CFTR on at least one allele comprising administering to said patient form D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, W, or Hydrate B, or any combination of these forms, as described herein.
  • the method includes treating or lessening the severity of cystic fibrosis in a patient possessing the G551D mutation of human CFTR on both alleles comprising administering to said patient form D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, W, or Hydrate B, or any combination of these forms, as described herein.
  • the present invention provides a method of treating or lessening the severity of a condition, disease, or disorder implicated by CFTR mutation.
  • the present invention provides a method of treating a condition, disease, or disorder implicated by a deficiency of the CFTR activity, the method comprising administering a composition comprising forms D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, W, or Hydrate B, or any combination of these forms as described herein, to a subject, preferably a mammal, in need thereof.
  • the present invention provides a method of treating diseases associated with reduced CFTR function due to mutations in the gene encoding CFTR or environmental factors (e.g., smoke).
  • diseases include, cystic fibrosis, chronic bronchitis, recurrent bronchitis, acute bronchitis, male infertility caused by congenital bilateral absence of the vas deferens (CB AVD), female infertility caused by congenital absence of the uterus and vagina (CAUV), idiopathic chronic pancreatitis (ICP), idiopathic recurrent pancreatitis, idiopathic acute pancreatitis, chronic rhinosinusitis, primary sclerosing cholangitis, allergic bronchopulmonary aspergillosis, diabetes, dry eye, constipation, allergic bronchopulmonary aspergillosis (ABPA), bone diseases (e.g., osteoporosis), and asthma, comprising administering to said
  • the present invention provides a method for treating diseases associated with normal CFTR function.
  • diseases include, chronic obstructive pulmonary disease (COPD), chronic bronchitis, recurrent bronchitis, acute bronchitis, rhinosinusitis, constipation, pancreatitis including chronic pancreatitis, recurrent pancreatitis, and acute pancreatitis, pancreatic insufficiency, male infertility caused by congenital bilateral absence of the vas deferens (CBAVD), mild pulmonary disease, idiopathic pancreatitis, liver disease, hereditary emphysema, gallstones, gastroesophageal reflux disease, gastrointestinal
  • malignancies inflammatory bowel disease, constipation, diabetes, arthritis, osteoporosis, and osteopenia, comprising administering to said patient form D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, W, or Hydrate B, or any combination of these forms, as described herein.
  • the present invention provides a method for treating diseases associated with normal CFTR function including hereditary hemochromatosis, coagulation- fibrinolysis deficiencies, such as protein C deficiency, Type 1 hereditary angioedema, lipid processing deficiencies, such as familial hypercholesterolemia, Type 1 chylomicronemia, abetalipoproteinemia, lysosomal storage diseases, such as I-cell disease/pseudo-Hurler, mucopolysaccharidoses, Sandhof/Tay-Sachs, Crigler-Najjar type II,
  • diseases associated with normal CFTR function including hereditary hemochromatosis, coagulation- fibrinolysis deficiencies, such as protein C deficiency, Type 1 hereditary angioedema, lipid processing deficiencies, such as familial hypercholesterolemia, Type 1 chylomicronemia, abetalipoproteinemia, lysosomal storage diseases, such as I-cell disease/pseudo-H
  • polyendocrinopathy/hyperinsulinemia Diabetes mellitus, Laron dwarfism, myeloperoxidase deficiency, primary hypoparathyroidism, melanoma, glycanosis CDG type 1 , congenital hyperthyroidism, osteogenesis imperfecta, hereditary hypofibrinogenemia, ACT deficiency, Diabetes insipidus (DI), neurohypophyseal DI, nephrogenic DI, Charcot-Marie Tooth syndrome, Pelizaeus-Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, progressive supranuclear palsy, Pick's disease, several polyglutamine neurological disorders such as Huntington's, spinocerebellar ataxia type I, spinal and bulbar muscular atrophy, dentatorubral pallidoluysian atrophy, and myotonic dystrophy, as well as spongiform ence
  • the present invention provides a method of treating cystic fibrosis comprising the step of administering to said mammal a composition comprising the step of administering to said mammal an effective amount of a composition comprising Forms D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, W, or Hydrate B, or any combination of these forms, described herein.
  • an "effective amount" of Forms D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, W, or Hydrate B, any combination of these forms, or a pharmaceutically acceptable composition thereof is that amount effective for treating or lessening the severity of one or more of the diseases, disorders or conditions as recited above.
  • Forms D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, W, or Hydrate B, or any combination of these forms, or a pharmaceutically acceptable composition thereof may be administered using any amount and any route of administration effective for treating or lessening the severity of one or more of the diseases, disorders or conditions as recited above.
  • Forms D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, W, or Hydrate B, any combination of these forms, or a pharmaceutically acceptable composition thereof is useful for treating or lessening the severity of cystic fibrosis in patients who exhibit residual CFTR activity in the apical membrane of respiratory and non-respiratory epithelia.
  • the presence of residual CFTR activity at the epithelial surface can be readily detected using methods known in the art, e.g., standard electrophysiological, biochemical, or histochemical techniques.
  • Such methods identify CFTR activity using in vivo or ex vivo electrophysiological techniques, measurement of sweat or salivary CI " concentrations, or ex vivo biochemical or histochemical techniques to monitor cell surface density. Using such methods, residual CFTR activity can be readily detected in patients heterozygous or homozygous for a variety of different mutations, including patients homozygous or heterozygous for the most common mutation, AF508.
  • Forms D, E, F, G, H, I, J, , L, M, N, O, P, Q, R, S, T, W, or Hydrate B, or any combination of these forms, described herein or a pharmaceutically acceptable composition thereof, is useful for treating or lessening the severity of cystic fibrosis in patients who have residual CFTR activity induced or augmented using pharmacological methods or gene therapy. Such methods increase the amount of CFTR present at the cell surface, thereby inducing a hitherto absent CFTR activity in a patient or augmenting the existing level of residual CFTR activity in a patient.
  • Forms D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, W, or Hydrate B, or any combination of these forms, described herein, or a pharmaceutically acceptable composition thereof is useful for treating or lessening the severity of cystic fibrosis in patients within certain genotypes exhibiting residual CFTR activity, e.g., class III mutations (impaired regulation or gating), class IV mutations (altered conductance), or class V mutations (reduced synthesis) (Lee R.
  • patient genotypes that exhibit residual CFTR activity include patients homozygous for one of these classes or heterozygous with any other class of mutations, including class I mutations, class II mutations, or a mutation that lacks classification.
  • Forms D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, W, or Hydrate B, or any combination of these forms described herein or a pharmaceutically acceptable composition thereof is useful for treating or lessening the severity of cystic fibrosis in patients within certain clinical phenotypes, e.g., a moderate to mild clinical phenotype that typically correlates with the amount of residual CFTR activity in the apical membrane of epithelia.
  • Such phenotypes include patients exhibiting pancreatic insufficiency or patients diagnosed with idiopathic pancreatitis and congenital bilateral absence of the vas deferens, or mild lung disease.
  • the exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular agent, its mode of administration, and the like.
  • the compounds of the invention are preferably formulated in dosage unit form for ease of administration and uniformity of dosage.
  • dosage unit form refers to a physically discrete unit of agent appropriate for the patient to be treated. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment.
  • the specific effective dose level for any particular patient or organism will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed, and like factors well known in the medical arts.
  • patient means an animal, preferably a mammal, and most preferably a human.
  • compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, drops or patch), bucally, as an oral or nasal spray, or the like, depending on the severity of the infection being treated.
  • the compounds of the invention may be administered orally or parenterally at dosage levels of about 0.01 mg/kg to about 50 mg/kg and preferably from about 0.5 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect.
  • Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
  • the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • the oral compositions can also include
  • Injectable preparations for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
  • the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil can be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid are used in the preparation of injectables.
  • the injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
  • the rate of compound release can be controlled.
  • biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.
  • compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating agents.
  • excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
  • the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin,
  • the dosage form may also comprise buffering agents.
  • Solid compositions of a similar type may also be employed as fillers in soft and hard- filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner.
  • embedding compositions examples include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polethylene glycols and the like.
  • the active compounds can also be in microencapsulated form with one or more excipients as noted above.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art.
  • the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch.
  • Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose.
  • the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner.
  • embedding compositions examples include polymeric substances and waxes.
  • Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches.
  • the active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required.
  • Ophthalmic formulation, eardrops, and eye drops are also contemplated as being within the scope of this invention.
  • the present invention contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of a compound to the body.
  • Such dosage forms are prepared by dissolving or dispensing the compound in the proper medium.
  • Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
  • Forms D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, W, or Hydrate B, or any combination thereof described herein or a pharmaceutically acceptable composition thereof can be employed in combination therapies, that is, Forms D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, W, or Hydrate B, or any combination thereof described herein or a pharmaceutically acceptable composition thereof, can be administered concurrently with, prior to, or subsequent to, one or more other desired therapeutics or medical procedures.
  • the particular combination of therapies (therapeutics or procedures) to employ in a combination regimen will take into account compatibility of the desired therapeutics and/or procedures and the desired therapeutic effect to be achieved. It will also be appreciated that the therapies employed may achieve a desired effect for the same disorder (for example, an inventive compound may be administered concurrently with another agent used to treat the same disorder), or they may achieve different effects (e.g., control of any adverse effects). As used herein, additional therapeutic agents that are normally administered to treat or prevent a particular disease, or condition, are known as "appropriate for the disease, or condition, being treated.”
  • the additional agent is selected from a mucolytic agent, bronchodilator, an anti-biotic, an anti-infective agent, an anti-inflammatory agent, a CFTR modulator other than a compound of the present invention, or a nutritional agent.
  • the additional agent is an antibiotic.
  • antibiotics useful herein include tobramycin, including tobramycin inhaled powder (TIP), azithromycin, aztreonam, including the aerosolized form of aztreonam, amikacin, including liposomal formulations thereof, ciprofloxacin, including formulations thereof suitable for administration by inhalation, levoflaxacin, including aerosolized formulations thereof, and combinations of two antibiotics, e.g., fosfomycin and tobramycin.
  • the additional agent is a mucolyte.
  • exemplary mucolytes useful herein includes Pulmozyme®.
  • the additional agent is a bronchodilator.
  • bronchodilators include albuterol, metaprotenerol sulfate, pirbuterol acetate, salmeterol, or tetrabuline sulfate.
  • the additional agent is effective in restoring lung airway surface liquid.
  • Such agents improve the movement of salt in and out of cells, allowing mucus in the lung airway to be more hydrated and, therefore, cleared more easily.
  • Exemplary such agents include hypertonic saline, denufosol tetrasodium ([[(3S, 5R)-5-(4-amino-2-oxopyrimidin-l-yl)- 3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-l- yl)-3, 4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate), or bronchitol (inhaled formulation of mannitol).
  • the additional agent is an anti-inflammatory agent, i.e., an agent that can reduce the inflammation in the lungs.
  • agents useful herein include ibuprofen, docosahexanoic acid (DHA), sildenafil, inhaled glutathione, pioglitazone, hydroxychloroquine, or simavastatin.
  • the additional agent reduces the activity of the epithelial sodium channel blocker (ENaC) either directly by blocking the channel or indirectly by modulation of proteases that lead to an increase in ENaC activity (e.g., seine proteases, channel- activating proteases).
  • exemplary such agents include camostat (a trypsin-like protease inhibitor), QAU145, 552-02, GS-9411, INO-4995, Aerolytic, and amiloride.
  • Additional agents that reduce the activity of the epithelial sodium channel blocker (ENaC) can be found, for example in PCT Publication No. WO2009/074575, the entire contents of which are incorporated herein in their entirety.
  • CFTR modulators such as Forms D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, W, or Hydrate B
  • agents that reduce the activity of ENaC are used for treating Liddle's syndrome, an inflammatory or allergic condition including cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, respiratory tract infections (acute and chronic; viral and bacterial) and lung carcinoma.
  • Combinations of CFTR modulators such as Forms D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, W, or Hydrate B, and agents that reduce the activity of ENaC are also useful for treating diseases mediated by blockade of the epithelial sodium channel also include diseases other than respiratory diseases that are associated with abnormal fluid regulation across an epithelium, perhaps involving abnormal physiology of the protective surface liquids on their surface, e.g., xerostomia (dry mouth) or keratoconjunctivitis sire (dry eye). Furthermore, blockade of the epithelial sodium channel in the kidney could be used to promote diuresis and thereby induce a hypotensive effect.
  • diseases other than respiratory diseases that are associated with abnormal fluid regulation across an epithelium, perhaps involving abnormal physiology of the protective surface liquids on their surface, e.g., xerostomia (dry mouth) or keratoconjunctivitis si
  • Asthma includes both intrinsic (non-allergic) asthma and extrinsic (allergic) asthma, mild asthma, moderate asthma, severe asthma, bronchitic asthma, exercise-induced asthma, occupational asthma and asthma induced following bacterial infection.
  • Treatment of asthma is also to be understood as embracing treatment of subjects, e.g., of less than 4 or 5 years of age, exhibiting wheezing symptoms and diagnosed or diagnosable as "whez infants", an established patient category of major medical concern and now often identified as incipient or early-phase asthmatics.
  • Prophylactic efficacy in the treatment of asthma will be evidenced by reduced frequency or severity of symptomatic attack, e.g., of acute asthmatic or bronchoconstrictor attack, improvement in lung function or improved airways hyperreactivity. It may further be evidenced by reduced requirement for other, symptomatic therapy, i.e., therapy for or intended to restrict or abort symptomatic attack when it occurs, e.g., anti-inflammatory (e.g., cortico-steroid) or bronchodilatory. Prophylactic benefit in asthma may, in particular, be apparent in subjects prone to "morning dipping".
  • “Morning dipping” is a recognized asthmatic syndrome, common to a substantial percentage of asthmatics and characterized by asthma attack, e.g., between the hours of about 4-6 am, i.e., at a time normally substantially distant from any previously administered symptomatic asthma therapy.
  • Chronic obstructive pulmonary disease includes chronic bronchitis or dyspnea associated therewith, emphysema, as well as exacerbation of airways hyperreactivity consequent to other drug therapy, in particular, other inhaled drug therapy.
  • the combinations of CFTR modulators such as Forms D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, W, or Hydrate B, and agents that reduce the activity of ENaC are useful for the treatment of bronchitis of whatever type or genesis including, e.g., acute, arachidic, catarrhal, croupus, chronic or phthinoid bronchitis.
  • the additional agent is a CFTR modulator other than Form XX, Forms D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, W, or Hydrate B, i.e., an agent that has the effect of modulating CFTR activity.
  • CFTR modulator other than Form XX, Forms D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, W, or Hydrate B, i.e., an agent that has the effect of modulating CFTR activity.
  • exemplary such agents include ataluren
  • PTC124® 3-[5-(2-fluorophenyl)-l,2,4-oxadiazol-3-yl]benzoic acid), sinapultide, lancovutide, depelestat (a human recombinant neutrophil elastase inhibitor), cobiprostone (7- ⁇ (2R, 4aR, 5R, 7aR)-2-[(3S)-l,l-difluoro-3-methylpentyl]-2-hydroxy-6- oxooctahydrocyclopenta[b]pyran-5-yl ⁇ heptanoic acid), or (3-(6-(l-(2,2- difluorobenzo[d][l,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid.
  • the additional agent is (3-(6-(l-(2,2-difluorobenzo[d][l,3]dioxol- 5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid.
  • the additional agent is a nutritional agent.
  • exemplary such agents include pancrelipase (pancreating enzyme replacement), including Pancrease®,
  • the additional nutritional agent is pancrelipase.
  • the additional agent is a CFTR modulator other than a compound of the present invention.
  • compositions of this invention will be no more than the amount that would normally be administered in a
  • composition comprising that therapeutic agent as the only active agent.
  • amount of additional therapeutic agent in the presently disclosed compositions will range from about 50 % to 100 % of the amount normally present in a composition comprising that agent as the only therapeutically active agent.
  • Forms D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, W, or Hydrate B, or any combination thereof described herein or a pharmaceutically acceptable composition thereof may also be incorporated into compositions for coating an implantable medical device, such as prostheses, artificial valves, vascular grafts, stents and catheters.
  • the present invention in another aspect, includes a composition for coating an implantable device comprising a compound of the present invention as described generally above, and in classes and subclasses herein, and a carrier suitable for coating said implantable device.
  • the present invention includes an implantable device coated with a composition comprising a compound of the present invention as described generally above, and in classes and subclasses herein, and a carrier suitable for coating said implantable device.
  • Suitable coatings and the general preparation of coated implantable devices are described in US Patents 6,099,562; 5,886,026; and 5,304,121.
  • the coatings are typically biocompatible polymeric materials such as a hydrogel polymer, polymethyldisiloxane, polycaprolactone, polyethylene glycol, polylactic acid, ethylene vinyl acetate, and mixtures thereof.
  • the coatings may optionally be further covered by a suitable topcoat of fluorosilicone, polysaccarides, polyethylene glycol,
  • phospholipids or combinations thereof to impart controlled release characteristics in the composition.
  • Another aspect of the invention relates to modulating CFTR activity in a biological sample or a patient (e.g., in vitro or in vivo), which method comprises administering to the patient, or contacting said biological sample with Forms D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, W, or Hydrate B, or any combination thereof described herein or a pharmaceutically acceptable composition thereof.
  • biological sample includes, without limitation, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.
  • Modulation of CFTR in a biological sample is useful for a variety of purposes that are known to one of skill in the art. Examples of such purposes include, but are not limited to, the study of CFTR in biological and pathological phenomena; and the comparative evaluation of new modulators of CFTR.
  • a method of modulating activity of an anion channel in vitro or in vivo comprising the step of contacting said channel with Forms D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, W, or Hydrate B, or any combination thereof described herein or a pharmaceutically acceptable composition thereof.
  • the anion channel is a chloride channel or a bicarbonate channel. In other preferred embodiments, the anion channel is a chloride channel.
  • the present invention provides a method of increasing the number of functional CFTR in a membrane of a cell, comprising the step of contacting said cell with Forms D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, W, or Hydrate B, or any combination thereof described herein or a pharmaceutically acceptable composition thereof.
  • the activity of the CFTR is measured by measuring the transmembrane voltage potential.
  • Means for measuring the voltage potential across a membrane in the biological sample may employ any of the known methods in the art, such as optical membrane potential assay or other electrophysiological methods.
  • the optical membrane potential assay utilizes voltage-sensitive FRET sensors described by Gonzalez and Tsien (Se ⁇ Gonzalez, J. E. and R. Y. Tsien (1995) "Voltage sensing by fluorescence resonance energy transfer in single cells.” Biophys J69(4): 1272-80, and Gonzalez, J. E. and R. Y. Tsien (1997); "Improved indicators of cell membrane potential that use fluorescence resonance energy transfer” Chem Biol 4(4): 269-77) in combination with instrumentation for measuring fluorescence changes such as the Voltage/Ion Probe Reader (VIPR) (See i Gonzalez, J. E., K. Oades, et al. (1999) "Cell-based assays and instrumentation for screening ion-channel targets” Drug Discov Today 4(9): 431-439).
  • VIPR Voltage/Ion Probe Reader
  • the present invention provides a kit for use in measuring the activity of CFTR or a fragment thereof in a biological sample in vitro or in vivo comprising (i) a composition comprising Forms D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, W, or Hydrate B, or any combination thereof or any of the above embodiments; and (ii) instructions for a) contacting the composition with the biological sample and b) measuring activity of said CFTR or a fragment thereof.
  • the kit further comprises instructions for a) contacting an additional composition with the biological sample; b) measuring the activity of said CFTR or a fragment thereof in the presence of said additional compound, and c) comparing the activity of the CFTR in the presence of the additional compound with the density of the CFTR in the presence of Forms D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, W, or Hydrate B, or any combination thereof described herein.
  • the kit is used to measure the density of CFTR.
  • the invention provides a kit for use in measuring the activity of CFTR or a fragment thereof in a biological sample in vitro or in vivo, comprising:
  • composition comprising crystalline solvate Form D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, W, or Hydrate B, or combinations thereof;
  • the kit further comprises instructions for:
  • the step of comparing the activity of said CFTR, or fragment thereof provides a measure of the density of said CFTR, or fragment thereof
  • Amorphous Compound 1 or neat amorphous Compound 1 was used for slurry experiments in acetonitrile / water and isopropyl acetate/ water solvent systems as well as in methyl ethyl ketone (MEK)/ water solvent systems.
  • MEK methyl ethyl ketone
  • the reaction mixture was washed with water (10.0 vol.) 3 times. 2- MeTHF was charged to bring the total volume of reaction to 40.0 vol. (-16.5 vol. charged). Residual water was removed by continuous distillation at 35.0 °C +/- 5 °C from 40 vol. to 30 vol. with 2-MeTHF until in-process control testing using the Karl Fisher method shows the water content to be no more than 1.0% w/w.
  • the solution was cooled to 20.0 °C +/- 5.0 °C. To this solution was charged NaOMe/MeOH (1.7 equiv) to perform the hydrolysis of the carbonate. The reaction was stirred for no less than 1.0 hours, and checked for completion by HPLC.
  • Spray drying was performed on a Buchi Mini Spray Dryer B-290 with dehumidifier B-296 and Inert Loop B-295 using the parameters used in Table B.
  • a solvent system of MEK and DI water formulated according to the ratio 90 wt% MEK / 10 wt% DI water, was heated to a temperature of 20 - 30 °C in a reactor, equipped with a portable agitator and thermal circuit.
  • hypromellose acetate succinate polymer HPMCAS
  • SLS hypromellose acetate succinate polymer
  • N-[2,4-Bis(l,l-dimethylethyl)-5-hydroxyphenyl]-l,4- dihydro-4-oxoquinoline-3-carboxamide were added according to the ratio 19.5 wt%
  • the mixture was maintained at a temperature of 22-26 °C and mixed until it was substantially homogenous and all components were substantially dissolved.
  • the spray nozzle was situated approximately 5 cm from the top of the spray drying vessel. The solution was manually agitated during spray drying using a HDPE spatula.
  • a high efficiency cyclone separated the wet product from the spray gas and solvent vapors.
  • the wet product was transferred to a tray vacuum dryer for drying to reduce residual solvents to a level of less than about 5000 ppm.
  • the jacket temperature was kept at 60 °C for the first 8 hours and then increased to 80 °C.
  • XPRD Analysis The XRPD patterns were acquired with either a Bruker D8 Discover or Bruker D8 Advance diffractometer.
  • the Bruker D8 Advance system was used to characterize the starting materials and the results of the slurry experiments in the MEK/water solvent system in the presence of the polymeric additives that include hyromellose acetate succinate (HPMCAS), and sodium lauryl sulfate (SLS) Fischer Scientific.
  • HPMCAS hyromellose acetate succinate
  • SLS sodium lauryl sulfate
  • the Bruker D8 Discover system was used for all other XRPD acquisitions. All XRPD diffractograms were evaluated using DIFFRAC plus released 2006, EVA version 12.0 revision 0 software.
  • Bruker D8 Advance System The XRPD patterns were recorded at room temperature in reflection mode using a Bruker D8 Advance diffractometer equipped with a sealed tube Cu source and a Vantec PSD detector (Bruker AXS, Madison, WI). The X-ray generator was operating at a voltage of 40 kV and a current of 40 mA. The powder sample was placed in a silicon or PMM holder. The data were recorded in a ⁇ - ⁇ scanning mode over the range of 4°-45° 2 ⁇ with a step size of 0.014° and a dwell time of Is per step. Fixed divergence slits of 0.2 mm were used.
  • Bruker D8 Discover diffractometer equipped with a sealed tube source and a Hi-Star area detector (Bruker AXS, Madison, WI).
  • the X-Ray generator was operating at a voltage of 40 kV and a current of 35 mA.
  • the powder sample was placed in an aluminum holder. Two frames were registered with an exposure time of 120 s each. The data were subsequently integrated over the range of 4°-40° 2 ⁇ with a step size of 0.02° and merged into one continuous pattern.
  • TGA Thermogravimetric Analysis
  • Single-crystal analysis Single crystal diffraction was performed on a Bruker APEX II CCD diffractometer, with Cu Kct radiation by using single crystals picked from mother liquors and mounted on glass fibers. Oscillation photos were taken around ⁇ axis at 4 ⁇ angles. The data were indexed, integrated, and scaled with APEX software. The structures were solved and refined with the SHELX-TL package. The data collection was performed at a temperature of 100 Kelvin.
  • a polymorph screen was conducted in the methylethyl ketone (MEK)/ water solvent systems, as well as in the acetonitrile (ACN), ACN/water and isopropyl acetate solvent systems.
  • Polymorph screening techniques included crash cooling, solvent evaporation, antisolvent addition, and slurry experiments.
  • a range of solvent ratios were investigated for each technique and are listed in Tables 1 A, IB, 9, 12 and 14.
  • Slurry experiments were performed on an IKA RCT hot plate with magnetic stirring set to 710 rpm. The temperature was controlled with an IKA ETS-D5 thermocouple. Solvent volumes were measured and transferred with Gibson Pipetteman volumetric pipettes.
  • New forms that were identified as solvates were subjected to desolvation under two potential conditions: (1) drying in a vacuum oven at 40°C and (2) sitting undisturbed under ambient conditions in a fume hood. Physical characterization of all forms proceeded by X-ray powder diffraction (XRPD) and thermogravimetric analysis (TGA).
  • XRPD X-ray powder diffraction
  • TGA thermogravimetric analysis
  • a saturated solution of Compound 1 , Form XX was made by preparing 1 mL slurries using acetonitrile (ACN), ACN- water (75:25), methylethyl ketone (MEK), or MEK-water (99:1, 90:10, or 80:20) in vials. After 24 hours in capped HPLC vials, the slurries were then filtered to remove residual solids. Approximately 2 additional milligrams of Compound 1 was added to each vial containing a saturated solution. Next, the vials were heated to 70°C with stirring until all of the material was completely dissolved. Immediately after, the samples were submerged into an ice bath. The product, which precipitated as a white powder within 1 minute, was isolated by filtration and analyzed by XRPD and TGA.
  • XRPD analysis showed the same unique powder patterns (see, e.g., Figure 4) for the MEK and all MEK/water ratio samples, indicating that all four solvent systems produce the same isostructural form upon crash cooling regardless of water concentration.
  • TGA of the precipitate showed a 4.8% weight loss upon heating to 200°C ( Figure 5). The precipitate was thus determined to be a new form of
  • Form E Compound 1 , designated Form E, on the basis of its unique XRPD pattern.
  • Form E is likely a solvate based on the TGA data.
  • the peak list for Form E is provided in Table 3.
  • Form E is characterized by one or more peaks in an XRPD spectrum selected from the peaks listed in Table 3.
  • a saturated solution was made by slurrying Compound 1 , Form XX in 5 mL of solvent (ACN, isopropyl acetate (IP Ac), or MEK) or 1 mL of solvent for the MEK/Water solvent system. After 24 hours, the residual solids were removed by filtration. The saturated solutions were then subjected to rapid solvent evaporation by blowing nitrogen (N 2 ) gas over the samples with a Pierce Model 18780 Reacti-Vap evaporating unit for four hours. The product precipitated as a white powder and the form was analyzed by XRPD and TGA.
  • each of the unique forms were determined to be new forms of Compound 1 designated as Form G from IP Ac and Form H from IP Ac/water on the basis of the unique XRPD patterns.
  • Form G and Form H are likely solvates based on the TGA results.
  • the peak list for Form G is provided in Table 5.
  • Form G is characterized by one or more peaks in an XRPD spectrum selected from the peaks listed in Table 5.
  • Form H is characterized by one or more peaks in an XRPD spectrum selected from the peaks listed in Table 6.
  • Form I the forms precipitated from MEK and MEK/Water (99:1) were determined to be new forms of Compound 1, designated as Form I from MEK and Form J from MEK/water (99:1) on the basis of the unique XRPD patterns.
  • Form I and Form J are likely solvates based on the TGA results.
  • the peak list for Form I is provided in Table 7.
  • Form I is characterized by one or more peaks in an XRPD spectrum selected from the peaks listed in Table 7.
  • Form J is characterized by one or more peaks in an XRPD spectrum selected from the peaks listed in Table 8.
  • a saturated solution of Compound 1 , Form XX was made by slurrying either in 5 mL of solvent in the ACN, IP Ac, and MEK solvent systems, 2 mL total solvent for IP Ac/water, or 1 mL total solvent for the MEK/water solvent systems. After 24 hours, the residual solids were removed by filtration. 20 mL of antisolvent was then quickly added to the saturated solutions to induce precipitation. Hexane was used as the antisolvent in the MEK and IP Ac solvent systems, and MTBE was used as the antisolvent in the ACN solvent systems, as a consequence of the immiscibility between ACN and hexane. The product precipitated as a white powder and the form was analyzed by XRPD and TGA. The results of rapid antisolvent addition into saturated solutions of Compound 1 are listed in Table 9.
  • a precipitate was not initially obtained from hexane antisolvent addition into a saturated solution of Compound 1 in IP Ac.
  • a precipitate was not initially obtained from hexane antisolvent addition into a saturated solution of Compound 1 in IP Ac/water.
  • the clear solution was allowed to stand in a capped vial for several days after which clear rod shaped single crystals grew at the bottom of the vial.
  • the single crystal structure solution showed a centrosymmetric structure with space group C2/c. Disordered solvent was apparent within pockets and propagated through channels in the structure. The degree of disorder was such that no attempt was made to assign the atom identities and so the solvent was simply modeled as disordered electron density.
  • TGA of the single crystals resulted in a 0.4% weight loss upon heating to 100°C with a further 4.8% weight loss between 100°C and 200°C as a result of desolvation (Figure 35).
  • Simulation of the XRPD pattern from the single crystal data resulted in a unique pattern ( Figure 34).
  • Form T The peak list for Form T is provided in Table 10.
  • Form T is characterized by one or more peaks in an XRPD spectrum selected from the peaks listed in Table 10.
  • Form K is a new form of Compound 1 designated Form K on the basis of its unique XRPD pattern.
  • Form K is likely a solvate judging from TGA.
  • the peak list for Form K is provided in Table 11.
  • Form K is characterized by one or more peaks in an XRPD spectrum selected from the peaks listed in Table 11.
  • a white powder was collected by filtration from 24 hour and 2 week slurry experiments conducted at 25 °C and 70 °C in ACN and ACN/water. XRPD analysis of the samples results in peaks consistent with neat crystalline Form XX. When neat amorphous Compound 1 was slurried for 24 hours and 2 weeks in ACN and ACN/water at 25 °C and 70 °C neat Form XX was produced.
  • a white powder was collected by filtration from 24 hour and 2 week slurry experiments conducted at 25 °C and 70 °C in IP Ac and IP Ac/water.
  • XRPD analysis of the powder collected from the IP Ac and IP Ac/water samples slurried at 70 °C and IP Ac slurried at 25 °C results in peaks consistent with neat crystalline Form XX.
  • neat amorphous Compound 1 was slurried for 24 hours and 2 weeks in IP Ac and IP Ac/water at 70 °C and in IP Ac for 24 hours and 2 weeks at 25 °C, neat Form XX was produced.
  • a white powder was collected by filtration from the 24 hour and 2 week slurry experiments conducted at 25°C and 70°C in MEK, MEK/water (99:1), MEK/water (90:10) and MEK/water (80:20).
  • XRPD analysis of the powder collected from MEK/Water (90:10) and MEK/Water (80:20) samples at 25 °C after 24 hours and 2 weeks yielded a powder pattern that matched the powder pattern of Form E, indicating the precipitation of isostructural forms.
  • the powder collected from MEK/water (90:10) and MEK/water (80:20) slurried at 70 °C yielded XRPD patterns consistent with neat crystalline Form XX. Slurrying of neat amorphous
  • a white powder was collected by filtration from 24 hour and 2 week slurry experiments conducted at 25 °C and 70 °C in water.
  • XRPD analysis of the powder collected from samples slurried at 25 °C for 24 hours and 2 weeks in water resulted in powder patterns consistent with the known form of Hydrate A of Compound 1.
  • XRPD analysis of the powder collected from samples slurried at 70 °C demonstrated Compound 1 , Hydrate A formation after 24 hours and Compound 1, Form XX after 2 weeks.
  • Hydrate A was formed.
  • it was slurried at 70 °C Hydrate A was observed after 24 hours and Form XX was observed after 2 weeks.
  • Experiment 5 Slurry Experiments with Compound 1 Spray-Dried Dispersion in the Presence of HPMC-AS and SLS.
  • a white powder was collected by filtration from the 24 hour and 2 week slurry experiments conducted at 25 °C and 70 °C in MEK, MEK/water (99:1), MEK/water (90:10) and MEK/water (80:20). Analysis of the powder collected from samples slurried in MEK and MEK/water (99:1) at 2 5°C for 24 hours and 2 weeks yielded the same unique XRPD pattern for all four samples, indicating the synthesis of isostructural forms (Figure 20). TGA of the precipitate showed a 1.2% weight loss upon heating to 100 °C and a further 11.3% weight loss upon further heating between 100 °C and 200°C, attributable to loss of solvent (Figure 21).
  • Form M is a new form of Compound 1 designated Form M.
  • Form M is likely a solvate based on the TGA results.
  • the peak list for Form M is provided in Table 15.
  • Form M is characterized by one or more peaks in an XRPD spectrum selected from the peaks listed in Table 15.
  • MEK/water (80:20) in slurries carried out at 25°C produced a different form from MEK and MEK/ Water (99: 1 ) as judged from XRPD analysis at 24 hour and 2 week time points.
  • the same XRPD pattern was produced from MEK/water (90:10) and MEK/water (80:20) slurries after 24 hours and 2 weeks at 25 °C, indicating the precipitation of new isostructural forms (Figure 22).
  • TGA of the precipitate resulted in a 1.0% weight loss upon heating to 75 °C and a further 3.7% weight loss upon heating between 100 °C and 200 °C ( Figure 23).
  • Form N is likely a solvate based on the TGA results.
  • the peak list for Form N is provided in Table 16.
  • Form N is characterized by one or more peaks in an XRPD spectrum selected from the peaks listed in Table 16.
  • Form O The powder collected from the 24 hour and 2 week slurries at 70 °C in MEK was determined to be a new form of Compound 1 designated Form O.
  • the peak list for Form O is provided in Table 17.
  • Form O is characterized by one or more peaks in an XRPD spectrum selected from the peaks listed in Table 17.
  • XRPD of a spray dried dispersion containing amorphous Compound 1 with HPMC- AS and SLS slurried in MEK/water (99:1) at 70 °C yielded a diffraction pattern consistent with Form O after 24 hours and a diffraction pattern consistent with Form XX after 2 weeks.
  • XRPD of a spray dried dispersion containing amorphous Compound 1 slurried in MEK/water (90:10) at 70 °C yielded a unique diffraction pattern after 24 hours, indicating the synthesis of a new form of Compound 1 ( Figure 26), designated Form P and a diffraction pattern consistent with Form XX after 2 weeks.
  • TGA of Form P showed a 2.4% weight loss upon heating to 100 °C with a further 4.7% weight loss upon heating between 100 °C and 200 °C, indicating that Form P is likely a solvate (Figure 27).
  • the peak list for Form P is provided in Table 18.
  • Form P is characterized by one or more peaks in an XRPD spectrum selected from the peaks listed in Table 18.
  • Form G became x-ray amorphous after standing in the vacuum oven for one month.
  • Form H produced the same Form H pattern after standing under ambient conditions for one month but converted to a semi-crystalline form after standing in the vacuum oven for one month.
  • Form L produced the same Form L pattern after standing under ambient conditions for two weeks but converted to x-ray amorphous after standing in the vacuum oven for 24 hours.
  • Forms D and K produced new crystalline XRPD patterns following desolvation.
  • XRPD analysis of Form D after standing under ambient conditions and standing in the vacuum oven for approximately 1 month, showed a unique diffraction pattern, indicating that Form D had converted to a new crystalline form of Compound 1 designated Form R (Figure 30).
  • TGA of Form R showed a 2.1% weight loss upon heating to 200 °C, indicating that Form R had retained some solvent (Figure 31).
  • the peak list for Form R is provided in Table 20.
  • Form R is characterized by one or more peaks in an XRPD spectrum selected from the peaks listed in Table 20.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des formes de solvat cristallines de N-[2,4-bis(1,1- diméthyléthyle)-5-hydroxyphényle]-1,4-dihydro-4-oxoquinoline-3-carboxamide (composé 1) et leurs procédés de préparation. La présente invention concerne en outre des compositions pharmaceutiques comprenant les formes de solvat cristallines, ainsi que des procédés de traitement les utilisant.
EP12720324.8A 2012-04-20 2012-04-20 Formes solides de n-[2,4-bis(1,1-diméthyléthyle)-5-hydroxyphényle]-1,4-dihydro-4-oxoquinoline-3-carboxamide Withdrawn EP2838882A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/034578 WO2013158121A1 (fr) 2012-04-20 2012-04-20 Formes solides de n-[2,4-bis(1,1-diméthyléthyle)-5-hydroxyphényle]-1,4-dihydro-4-oxoquinoline-3-carboxamide

Publications (1)

Publication Number Publication Date
EP2838882A1 true EP2838882A1 (fr) 2015-02-25

Family

ID=46052877

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12720324.8A Withdrawn EP2838882A1 (fr) 2012-04-20 2012-04-20 Formes solides de n-[2,4-bis(1,1-diméthyléthyle)-5-hydroxyphényle]-1,4-dihydro-4-oxoquinoline-3-carboxamide

Country Status (4)

Country Link
EP (1) EP2838882A1 (fr)
AU (1) AU2012377446A1 (fr)
CA (1) CA2869847A1 (fr)
WO (1) WO2013158121A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2815749A1 (fr) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Forme solide de 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione ayant un réseau de diffraction de rayons X spécifique
CA2927661A1 (fr) * 2013-11-13 2015-05-21 Apotex Inc. Formes solides d'ivacaftor et processus de preparation de celles-ci
SI3203840T1 (sl) 2014-10-06 2020-10-30 Vertex Pharmaceuticals Incorporated Modulatorji regulatorja transmembranske prevodnosti pri cistični fibrozi
CA2963945C (fr) * 2014-10-07 2023-01-10 Vertex Pharmaceuticals Incorporated Co-cristaux de modulateurs du regulateur de conductance transmembranaire de la mucoviscidose
WO2016092561A2 (fr) * 2014-12-09 2016-06-16 Laurus Labs Private Limited Nouveaux polymorphes d'ivacaftor, procédé de préparation de cette molécule et composition pharmaceutique la contenant
WO2018064632A1 (fr) 2016-09-30 2018-04-05 Vertex Pharmaceuticals Incorporated Modulateur de régulateur de conductance transmembranaire de fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur
MX2019006637A (es) 2016-12-09 2019-08-21 Vertex Pharma Modulador del regulador de conductancia transmembrana de fibrosis quistica composiciones farmaceuticas metodos de tratamiento y proceso para producir el modulador.
AU2018279646B2 (en) 2017-06-08 2023-04-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
EP3654969A1 (fr) 2017-07-17 2020-05-27 Vertex Pharmaceuticals Incorporated Méthodes de traitement de la fibrose kystique
JP7121794B2 (ja) 2017-08-02 2022-08-18 バーテックス ファーマシューティカルズ インコーポレイテッド ピロリジン化合物を調製するためのプロセス
AU2018351533B2 (en) 2017-10-19 2023-02-02 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
MX2020005753A (es) 2017-12-08 2020-08-20 Vertex Pharma Procesos para producir moduladores de regulador de conductancia transmembranal de fibrosis quistica.
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
MX2020008268A (es) 2018-02-15 2020-09-21 Vertex Pharma Macrociclos como moduladores del regulador de conductancia transmembrana de la fibrosis quistica, composiciones farmaceuticas de estos, su uso en el tratamiento de la fibrosis quistica y procesos para elaborarlos.
WO2019200246A1 (fr) 2018-04-13 2019-10-17 Alexander Russell Abela Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur
TW202120517A (zh) 2019-08-14 2021-06-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
CA3150162A1 (fr) 2019-08-14 2021-02-18 Vertex Pharmaceuticals Incorporated Formes cristallines de modulateurs de cftr
TW202115092A (zh) 2019-08-14 2021-04-16 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
US11384054B2 (en) 2020-10-22 2022-07-12 Scinopharm Taiwan, Ltd. Crystalline form of ivacaftor and a process for preparing the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
AU2005210474B2 (en) 2004-01-30 2011-07-07 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding cassette transporters
CN101891680B (zh) 2004-06-24 2014-10-29 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的调控剂
ES2624554T3 (es) * 2005-12-28 2017-07-14 Vertex Pharmaceuticals Incorporated Formas sólidas de n- [2,4 - bis (1,1 - dimetiletil) - 5 - hidroxifenil] - 1,4 - dihidro - 4 - oxoquinolina - 3 - carboxamida
NZ620027A (en) * 2007-09-14 2015-05-29 Vertex Pharma Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
WO2009074575A2 (fr) 2007-12-10 2009-06-18 Novartis Ag Composés organiques
NZ602557A (en) * 2010-03-19 2014-09-26 Vertex Pharma Solid form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2013158121A1 *

Also Published As

Publication number Publication date
WO2013158121A1 (fr) 2013-10-24
CA2869847A1 (fr) 2013-10-24
AU2012377446A1 (en) 2014-10-23

Similar Documents

Publication Publication Date Title
US9045425B2 (en) Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
AU2015330923B2 (en) Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
EP2838882A1 (fr) Formes solides de n-[2,4-bis(1,1-diméthyléthyle)-5-hydroxyphényle]-1,4-dihydro-4-oxoquinoline-3-carboxamide
AU2009308241B2 (en) Solid forms of N-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl) phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide
US8884018B2 (en) Process for preparing modulators of cystic fibrosis transmembrane conductance regulator
US8741922B2 (en) Solid forms of N-(4-(7-azabicyclo[2.2,1]heptan-7-yl)-2-trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide
WO2011146886A1 (fr) Procédés de production de modulateurs du régulateur de conductance transmembranaire de la fibrose kystique
NZ730805B2 (en) Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20141120

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LUISI, BRIAN

Inventor name: NEUBERT-LANGILLE, BOBBIANNA, J.

Inventor name: AREKAR, SNEHA GHANSHYAM

Inventor name: COSTACHE, ADRIANA

Inventor name: JOHNSTON, STEVEN, C.

Inventor name: DINEHART, KIRK RAYMOND

17Q First examination report despatched

Effective date: 20160722

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20161202